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ABSTRACT

HOSPITAL RESOURCE UTILIZATION AMONG PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE – AN ANALYSIS OF 2002 – 2005
HEALTHCARE COST AND UTILIZATION PROJECT DATA

By
Pallavi B. Rane
May 2010

Thesis supervised by: Dr. Khalid Kamal
Objective: The objective of this study is to develop a national assessment of the length of
stay (LOS), total costs, and in-hospital mortality among patients with chronic obstructive
pulmonary disease (COPD), using retrospective data derived from Nationwide Inpatient
Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP).
Methods: COPD- related hospitalizations using inpatient discharge-level data derived
from 2005 NIS was utilized. Records with principal diagnosis of COPD were extracted
using ICD-9 codes 490.xx-492.xx and 496.xx. Patient- (age, race, gender, payer, patient
location, and median household income) and hospital-related (region, location, hospital
bed size, type of admission type, and number of procedures on record) variables were
considered in the analysis. Descriptive analysis was conducted to examine the
differences in COPD-related hospital LOS, total hospital costs, and in-hospital mortality.
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Multiple regression was conducted to identify predictors of LOS, costs, and in-hospital
mortality among patients with COPD.
Results: An estimated total of 616,818 hospitalized cases for COPD as primary
diagnosis, and 1,426,723 cases for COPD as secondary diagnosis were identified. The
study showed that the burden of disease associated with COPD is substantially
underestimated, and that it usually affects females, Caucasians, people aged 65 and
above, and people from lower income level groups. It was also seen that COPD most
commonly affected people located in the metropolitan areas, and also those from the
southern region of the US. The mean LOS was found to be 4.69 and mean total costs
were found to be $6,939. An estimated 12,054 in-hospital deaths were observed with
COPD listed as the primary diagnosis. The study clearly demonstrated that disparities do
exist in occurrence of COPD, and the outcomes related to the disease. Number of
procedures and number of diagnoses listed on the record; were seen to be important
predictors for hospital LOS, total hospital costs as well as in-hospital mortality. Hospital
region, gender, and payer were among other important predictors for hospital LOS;
whereas for total hospital costs, important predictors included hospital region, race, and
patient location. Age and gender were seen to be important predictors of in-hospital
mortality. For the years 2002-2005, a decreasing trend in hospital LOS was observed,
while an increasing trend was observed for total hospital costs.
Conclusion: Hospital resource utilization is high in patients with COPD. Appropriate
disease management, and application of preventative care such as early disease
management for COPD, and the related co-morbidities in identified population, can help
in lowering hospital admission rates and costs associated with it.
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CHAPTER ONE
INTRODUCTION

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines,
formed by the United States (US) National Heart, Lung, and Blood Institute (NHLBI)
and the World Health Organization (WHO), define Chronic Obstructive Pulmonary
Disease (COPD) as a preventable and treatable disease with some significant
extrapulmonary effects that may contribute to the disease severity in individual patients.
COPD is an incessant disease characterized by decline in lung function and obstruction to
air flow that is not fully reversible.1, 2
The obstruction in the air flow is caused by a combination of obstructive
bronchitis and emphysema.1, 2 In obstructive bronchitis, the chronic inflammation of the
small airways leads to structural changes resulting in airflow limitation. In emphysema,
the inflammation causes destruction of the lung parenchyma. The parenchymal
destruction leads to loss of alveolar attachments to the small airways and decreases lung
elastic recoil, which impairs the ability of the airways during expiration. The relative
contribution of obstructive bronchitis and/or emphysema, to the disease severity may
vary from person to person.1
An exacerbation of COPD is defined as an event in the natural course of the
disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum
that is beyond normal day-to-day variations. An exacerbation is acute in onset, and may
warrant a change in regular medication in a patient with underlying COPD.1 Patients
with COPD on an average, have two exacerbations per year.3 Exacerbations are the main
1

cause of medical visits and hospitalizations, and they are associated with a high healthcare expenditure.4, 5 Exacerbations in COPD also have serious negative impact on
patient’s quality of life, lung function , and socioeconomic costs.1

Pathology, Pathogenesis, and Pathophysiology
Typical characteristics of pathological changes in COPD include chronic
inflammation with increased number of specific inflammatory cell types, and structural
changes resulting from repeated injury and repair. These changes occur in the proximal
airways, peripheral airways, lung parenchyma, and pulmonary vasculature. In patients
with COPD, the inflammation appears to be an amplification of the normal response of
the respiratory tract to chronic irritants such as cigarette smoke. COPD involves a
specific pattern of inflammation involving inflammatory cells like neutrophiles,
macrophages and lymphocytes. The inflammatory cells release inflammatory mediators
like chemotactic factors, proinflammatory cytokinines, and growth factors; which interact
with structural cells in the airways and lung parenchyma. Lung inflammation is further
amplified by oxidative stress or a protease-antiprotease imbalance.
Physiological changes in COPD include mucus hypersecretion, airflow limitation
and air trapping, gas exchange abnormalities, and cor pulmonale. The several systemic
features, especially in patients with severe COPD include cachexia, skeletal muscle
wasting, increased risk of cardiovascular disease, anemia, osteoporosis, and depression.
Exacerbations are a further amplification of the inflammatory responses in COPD, and
may be triggered by infection with bacteria or viruses or by environmental pollutants.1
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Epidemiology
COPD is considered to be a major cause of morbidity and mortality across the
world, and its prevalence continues to increase.6 Currently 12.1 million US adults (aged
≥ 18 years) are estimated to have been diagnosed with COPD and as many as 24 million
US adults have evidence of impaired lung function; indicating an under-diagnosis of
COPD.7 COPD can be described as an ill-defined mixture of overlapping manifestations
of chronic bronchitis, emphysema, and asthma. And because of the overlapping
symptoms associated with these conditions, COPD is often misdiagnosed or under
diagnosed.8 Additionally, variable definitions, and different diagnostic criteria of COPD
have significantly lead to the underestimation of COPD. Study results have shown that
the burden of disease associated with COPD is largely underestimated, as COPD is
usually listed as a secondary diagnosis.9 It has been found that morbidity due to COPD
increases with age and is greater in men than women. The prevalence of COPD has also
been found to be considerably higher in smokers and ex-smokers, and in individuals over
40 years of age.1, 10
COPD is the fourth leading cause of death in the US accounting for nearly 1.3
million lives in 2003, and it has been predicted to become the third most common cause
of mortality by 2020.7, 11 Trends in death rate in the US from 1970 through 2002 for the
six leading causes of death indicate; that while mortality from several of these chronic
conditions declined, mortality due to COPD increased during that period.2 The increase
in mortality rate in females due to COPD is also alarming. Between 1971 and 2000, a
five-fold increase in mortality rate was observed among females.12 In 2003 alone, 63,000
females died due to COPD as compared to 59,000 males.7 The increased and changing
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COPD mortality trend could be due to the expanding epidemic of smoking and the
changing demographics.11

Economic and Social Burden
The economic and social burden associated with COPD is enormous.1, 4 COPD is
a costly disease in terms of both direct and indirect costs.1 According to the NHLBI,
annual cost of COPD (2007 value) in the US was around $42.6 billion. This included
$26.7 billion in direct health care expenditures, $8 billion in indirect morbidity costs, and
$7.9 billion in indirect mortality costs.7 Hospitalization accounted for a major portion
($11.3 billion) of the direct health care expenditure. The total cost of care for patients is
significantly increased due to presence of COPD, especially in terms of inpatient costs.
The per capita expenditures for hospitalizations of COPD patients were found to be 2.7
times the expenditures for patients without COPD.13 Also, a direct relationship exists
between the severity of COPD and the cost of care. It has been reported that
hospitalization and ambulatory oxygen costs increase as the disease progresses.14
The social burden of COPD is also increasing and in terms of Disability-Adjusted
Life Years (DALYs) lost worldwide, COPD is expected to become the fifth leading cause
in 2020; from being the twelfth leading cause among all chronic diseases in 1990.15

Risk Factors
A number of risk factors have been attributed to the development of COPD.
Cigarette smoking is a major risk factor for COPD.1 It is widely believed that 15% of
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smokers develop COPD, however according to the recent US National Health and
Nutrition study (NHANES), sooner or later as many as 50% of the smokers may develop
COPD.16 Environmental or occupational exposure to lung irritants due to air pollution
from chemical fumes, vapors, and dusts; exposure to biomass smoke; early-life infections
and malnutrition have also been identified as a COPD risk factors.1, 9 COPD is a
progressive disease, particularly if the patient’s exposure to such noxious agents
continue.1 The hereditary deficiency of alpha-1 antitrypsin, a rare recessive genetic trait
most commonly seen in individuals of Northern European origin; is also reported as a
risk factor for COPD.2

COPD and Co‐morbidities
COPD generally develops in middle aged population, with a long smoking
history. And co-morbid conditions related to either smoking or aging, either already exist
in this population; or they are at an increased risk to develop such co-morbidities.17 The
extrapulmonary effects related to COPD itself can lead to other co-morbid conditions.
Some of the most common co-morbid conditions that have been described in association
with COPD include pneumonia, hypertension, diabetes, coronary artery disease, heart
failure, pulmonary infections, cancer, and pulmonary vascular disease. Studies have also
shown that co-morbidities in patients with COPD, especially cardiovascular diseases and
lung cancer play an important role in increasing the hospitalizations and risk of
mortality among patients with COPD.17

5

Disease Management
The GOLD guidelines suggest that an effective COPD management plan includes
four components - assess and monitor disease, reduce risk factors, manage stable COPD,
and manage exacerbations.1
Assessment and classification of COPD disease severity
The impact of COPD on patients depends not only on the degree of airflow
limitation but also on any existing co-morbidities, and the severity of disease symptoms.1
The symptoms of COPD include chronic and progressive dyspnea, breathlessness, and
decreased exercise capacity, cough, and sputum production.2 The diagnosis of COPD,
and determination of disease severity in COPD is usually done by the spirometry test.1
Spirometry measures the volume of air forcibly exhaled from the point of maximal
inspiration (forced vital capacity, FVC) and the volume of air exhaled during the first
second of this maneuver (forced expiratory volume in one second, FEV1). The ratio of
these two measurements (FEV1/FVC) is calculated, and the presence of airflow limitation
is defined by a post-bronchodilator FEV1/FVC < 0.70. The GOLD guidelines use
patient’s pulmonary function parameter such as post-bronchodilator FEV1, to classify
patients into different disease severity group (see Table1).2
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Table 1: Different stages of disease severity based on FEV1 value
Stage

Severity

FEV1 /FVC

I

Mild COPD

FEV1 /FVC < 0.70
FEV1 ≥ 80% predicted

II

Moderate COPD

FEV1 /FVC < 0.70
50% ≤ FEV1 < 80% predicted

III

Severe COPD

FEV1 /FVC < 0.70
30% ≤ FEV1 < 50% predicted

IV

Very Severe COPD

FEV1 /FVC < 0.70
FEV1< 30 % predicted

Adapted from Global strategy for the diagnosis, management, and prevention of Chronic Obstructive
Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2007.
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The different stages of COPD disease severity, based on GOLD guidelines are1
Stage I, Mild COPD: Characterized by mild airflow limitation, with or without chronic
cough and sputum production. At this stage, the individual is usually unaware that his or
her lung function is abnormal.
Stage II, Moderate COPD: Characterized by worsening airflow limitation, with
shortness of breath typically developing on exertion, cough and sputum production may
be present sometimes. At this stage, patients typically seek medical attention because of
chronic respiratory symptoms or an exacerbation of their disease.
Stage III, Severe COPD: Characterized by further worsening of airflow limitation,
greater shortness of breath, reduced exercise capacity, fatigue, and repeated exacerbations
that almost always have an impact on patient’s quality of life (QoL).
Stage IV, Very Severe COPD: Characterized by severe airflow limitation and presence
of respiratory failure. This may also lead to effects on the heart such as cor pulmonale
(right heart failure). At this stage, QoL is very appreciably impaired and exacerbations
may be life threatening.

8

Health-care interventions to reduce risk factors
Reduction of exposure to tobacco smoke, occupational dusts and chemicals, and
indoor and outdoor air pollutants; is essential for preventing the onset and progression of
COPD. This can be achieved with the help of public health initiatives including smoking
cessation, and protective steps taken by individual patients. It is suggested that
interventions that improve COPD outcomes by decreasing symptoms and preventing
acute exacerbations could substantially decrease the costs associated with COPD.18
The GOLD guidelines recognize smoking cessation as the single most effective
and cost-effective intervention in most people, to reduce the risk of developing COPD
and stop its progression. A review of data from several countries estimated the median
societal cost of various smoking cessation interventions at $990 to $13,000 per life year
gained.19
In the US, it is estimated that up to 19% of COPD in smokers and up to 31% of
COPD in nonsmokers may be attributable to occupational dust and fume exposure.1
Many occupationally induced respiratory disorders can be reduced or controlled through
strategies such as controlled airborne exposure at workplace and other strategies aimed at
reducing the burden of inhaled particles and gases.1

Management of stable COPD
GOLD has outlined guidelines for management of COPD. Pharmacotherapy is
used in COPD for preventing and controlling symptoms, reducing the frequency and
severity of exacerbations, improving health status, and improving exercise tolerance.1 A
step-wise treatment strategy is used in management of COPD, according to which the
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medications are presented in an order, based on the level of disease severity and clinical
symptoms.1 (Figure 1) The selection within each class of medication depends upon
individualized assessment of disease severity and the patient’s response.

10

Figure 1: Therapy at different stages of COPD.

Mild COPD

Severe
COPD

Moderate
COPD

Very Severe
COPD

Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)

Add regular treatment with one or more long-acting bronchodilators
(when needed); Add rehabilitation

Add inhaled glucocorticosteroids if repeated
exacerbations
Add long term
oxygen if chronic
respiratory failure
Consider surgical
treatments

Adapted from Global strategy for the diagnosis, management, and prevention of Chronic Obstructive
Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2007.
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Pharmacologic treatments
The classes of medications commonly used in treating COPD are
•

Bronchodilators (short and long acting)
β2 agonists: Albuterol (short acting), Salmeterol (long acting)
Anticholinergics: Ipratropium (short acting), Tiotropium (long acting)
Methylxanthines: Theophyline, Aminophylline

•

Inhaled glucocorticosteroids: Beclomethasone, Fluticasone.

Bronchodilators
Bronchodilators are central to the symptomatic management of COPD. They are
prescribed on an as-needed basis or on a regular basis to prevent or reduce symptoms and
exacerbations. The choice between β2 agonists, anticholinergics, and methylxanthines, or
combination therapy depends on the availability and the individual’s response in terms of
symptom relief and side effects. Combining bronchodilators may improve efficacy and
decrease the risk of side effects compared to increasing the dose of a single
bronchodilator. Regular treatment with long-acting bronchodilators is more effective and
convenient than treatment with short-acting bronchodilators.1

Glucocorticoids
Long term treatment with systemic glucocorticoids may cause side-effects such as
steroid myopathy in patients with advanced COPD. Thus chronic treatment with systemic
glucocorticoids should be avoided because of the unfavorable benefit-to-risk ratio.
However, the addition of regular treatment with inhaled glucocorticoids to bronchodilator
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treatment is appropriate for symptomatic COPD patients with severe COPD, very severe
COPD, and those with repeated exacerbations.

Other pharmacologic treatments
Other pharmacologic treatments used in the management of COPD include use of
vaccines, immunoregulators, antitussives, vasodilators and several other medications
which help in relieving symptoms and reducing the severity of exacerbations. Influenza
vaccines can reduce serious illness and death in COPD patients by about 50%.1 Influenza
vaccination has also been shown to reduce the risk of hospital admission and death in
elderly subjects with chronic lung disease.20

Non pharmacologic treatments
Non pharmacologic treatments include pulmonary rehabilitation, oxygen therapy,
ventilatory support, and surgical interventions.1

Pulmonary rehabilitation
A pulmonary rehabilitation program includes exercise training, nutrition
counseling and education. Pulmonary rehabilitation covers a range of non-pulmonary
problems (exercise de-conditioning, depression, muscle wasting, and weight loss) that
may not be adequately addressed by medical therapy for COPD. Pulmonary
rehabilitation has shown to reduce symptoms, anxiety and depression associated with
COPD. It has also reduced the number of hospitalizations, hospital length of stay, and
improved quality of life, and increased physical and emotional participation in everyday
activities.1
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Oxygen therapy
It is one of the principal nonpharmacologic treatments for patients with very
severe COPD. It can be administered in three ways: long-tem continuous therapy, during
exercise, and to relieve acute dyspnea. In patients with chronic respiratory failure, the
long-term administration of oxygen (> 15 hours per day) has shown to increase
survival.21

Ventilatory support
Noninvasive ventilation is now widely used to treat acute exacerbations of COPD.

Surgical treatments
Surgical treatments used in patients with COPD include bullectomy, lung volume
reduction surgery (LVRS), and lung transplantation.

Bullectomy
Bullectomy is used for bolus emphysema, and can be performed
thoracoscopically. It is effective in reducing dyspnea and improving lung function in
carefully selected patients.

Lung volume reduction surgery (LVRS)
In LVRS, parts of the lung are resected to reduce hyperinflation, making
respiratory muscles more effective pressure generators by improving their mechanical
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efficiency. LVRS also increases the elastic recoil pressure of the lung and improves
expiratory flow rates. It is an expensive palliative surgical procedure and can be
recommended only in carefully selected patients.

Lung transplantation
Lung transplantation has been shown to improve quality of life and functional
capacity in appropriately selected patients.

Management of Exacerbations
The impact of exacerbations is significant, and inhaled bronchodilators and oral
glucocorticosteroids are effective treatments for exacerbations of COPD. During
exacerbations, noninvasive mechanical ventilation has shown to improve respiratory
acidosis, decrease respiratory rate, severity of breathlessness, and decrease length of
hospital stay.1

PROBLEM STATEMENT

In 2000, COPD was responsible for eight million physician office and hospital
outpatient visits, 1.5 million emergency department visits, and 726,000 hospitalizations,
and 119,000 deaths in the US.7, 9 It is a leading cause of hospitalization in the older
population.18 Hospital admissions for COPD are mainly due to disease exacerbations and
respiratory failure.22 The rate of hospital readmissions is also particularly high for
exacerbations of COPD, with over half of the patients who are hospitalized for
15

exacerbations of COPD, being readmitted at least once in the following 6 months and a
majority of readmissions occurring within the first 3 months after hospital discharge.23
The frequency of readmission varies from 11.6% (48 hours after discharge from the
emergency room) to 63% (one year after admission to a general hospital).24 Because
hospitalization in patients with COPD usually occur in the later stages of the disease, it is
associated with a greater risk of mortality in the subsequent years.25 Mortality was found
to be 60% one year after hospitalization in patients 65 years and older, who were
hospitalized for exacerbation of COPD.25
As discussed earlier, hospitalizations account for a major portion of the total cost
of care in patients with COPD.1, 4 Some studies show that the cost of hospital stay
represents 40-57% of the total direct costs generated by patients with COPD, reaching up
to 63% in severe patients.26, 27 During an exacerbation, health-care utilization is usually
significantly increased, and thus, exacerbations are the key drivers of the costs of
COPD.16
The disparities in hospital resource utilization and factors associated with
hospitalization in COPD are poorly understood.24, 29-35 The influence of gender on the
susceptibility to and mortality from COPD is controversial. Some studies show an
increased risk of death in men with COPD, while other studies suggest that men are less
likely to die from COPD than women.29, 31, 32 There is a dearth of studies which have
done stratified analyses in the US population, to determine the effect of COPD according
to race, type of hospital, insurance, and socioeconomic status on the resulting differences
in health-care access, and on the risk of hospitalization and death .
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There is also a lack of information about differences between hospital types with
respect to length of stay (LOS) and mortality in a national sample in the US. Hence, in
this study, we will look at the characteristics of the patient population with COPD
utilizing hospital resources and evaluate the factors responsible for hospital resource
utilization, in-hospital mortality, and total hospitalization costs due to COPD. A study of
the rates of hospitalizations and duration of such hospital stays, due to COPD, can help us
understand the characteristics of the patient population and their level of resource
utilization.
Hospitalization for COPD could be avoided with appropriate management, use of
preventative care and early disease management.24 The study findings can help us
identify a subset of patients with COPD that could benefit best from an active
interventional program or a therapeutic strategy, which may help lowering hospital
readmission rates and costs, thereby reducing the economic burden of the disease.

CONCEPTUAL FRAMEWORK
The objective of this study is to develop a national assessment of hospital
resource usage in patients with COPD, using retrospective data derived from Nationwide
Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP). The
study will determine COPD- related hospitalizations using inpatient discharge-level data
for 100% of the discharges from a sample of hospitals in participating states, in terms of
patient and hospital characteristics. Temporal patterns (for years 2002-2005) of hospital
LOS, mortality during hospitalization, and total hospital costs due to COPD- related
hospitalizations will be identified.
17

The HCUP database was established by the Agency for Healthcare Research and
Quality (AHRQ) to provide multi-state, administrative, population-based data. It
contains set of information found in a typical discharge abstract including all listed
diagnosis and procedures, discharge status, patient demographics, and charges for all
patients- insured and uninsured in a uniform format.
HCUP provides five types of databases:
The State Inpatient Database (SID): It contains the universe of inpatient discharge
abstracts from community hospitals of the participating states.
The State Ambulatory Surgery Database (SASD): It contains data from ambulatory
care encounters in hospital-affiliated and sometimes freestanding ambulatory sites.
The State Emergency Department Database (SEDD): It contains data from hospital
affiliated emergency department abstracts for visits that do not result in a hospitalization.
The Kid’s Inpatient Database (KID): It contains a nationwide sample of inpatient
discharges of patients 18 years and younger.
The Nationwide Inpatient Sample (NIS): It is the largest all-payer inpatient care
database containing data from 5 to 8 million hospital stays from about 1000 hospitals
sampled to approximate a 20% stratified sample of US community hospitals.
We would be using the NIS database for our study.
The NIS is available from 1988 to 2005. It is the only national hospital database
with charge information on all patients, regardless of payer, including persons covered by
Medicare, Medicaid, private insurance and the insured. Researchers and policymakers
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use the NIS to identify, track, and analyze national trends in healthcare utilization, access,
charges, quality and outcomes.
The NIS contains patient-level clinical and resource use information included in a
typical discharge abstract. The NIS includes specialty hospitals such as obstetricsgynecology, ear-nose-throat, short term rehabilitation, orthopedic, pediatric, public
hospitals and academic medical centers. Excluded are long term hospitals, psychiatric
hospitals, alcoholism/chemical dependency treatment and short term rehabilitation
(beginning with 1998 data). The community hospitals are divided into strata using five
hospital characteristics: ownership/control, bed size, teaching status, urban/rural location
and US region.

OVERALL HYPOTHESIS
The overall hypothesis of this study is that disparities exist in hospital resource
utilization and mortality among patients with COPD.

STUDY OBJECTIVES
The specific objectives of this study would be:
1. To calculate and compare weighed averages for hospital length of stay (LOS),
total hospital costs, and in-hospital deaths; related to COPD as a primary and
secondary diagnosis using the 2005 NIS database.
2. To study the COPD-related hospitalizations in terms of patient and hospital
characteristics using the 2005 NIS database.
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3. To study the differences in the COPD-related hospital length of stay (LOS) by
patient and hospital characteristics using the 2005 NIS database.
4. To study the differences in the COPD-related hospital costs by patient and
hospital characteristics using the 2005 NIS database.
5. To study the differences in the COPD-related in-hospital mortality by patient
and hospital characteristics using the 2005 NIS database.
6. To identify predictors of COPD-related length of stay (LOS), in terms of
patient and hospital characteristics using the 2005 NIS database.
7. To identify predictors of COPD-related total hospital costs, in terms of patient
and hospital characteristics using the 2005 NIS database.
8. To identify predictors of in-hospital mortality in patients with COPD, in terms
of patient and hospital characteristics using the 2005 NIS database.
9. To study the temporal pattern of COPD-related hospital length of stay (LOS),
total hospital costs, and in-hospital deaths; between years 2002-2005, using
the NIS database.

SIGNIFICANCE OF THE STUDY

This study can help us identify the characteristics of patients with COPD , who
would benefit most from the interventional programs or preventive disease management
strategies. Also the study results can help us understand if there are disparities in access
to care in patients with COPD. This can help health care professionals in designing
health care policies and interventions targeting these high risk populations. This may
20

eventually help in delaying the progression of disease, preventing exacerbations and the
subsequent hospitalizations, reducing mortality in such population, and thus, alleviating
the economic burden associated with COPD.
Assessing patient- and hospital-related characteristics in COPD will help
understand the factors that influence the rate of hospital admissions, and the total cost of
hospitalization. This will further help assist health care professionals in making
important decisions regarding the management COPD, and eliminating COPD disparities.
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CHAPTER TWO
LITERATURE REVIEW

This chapter reviews the literature found on COPD-related hospitalizations and
important outcomes such as hospital LOS, total hospital charges, and in-hospital
mortality due to COPD-related hospitalizations. Information on trends in COPD-related
hospitalizations and predictors of such outcomes, have also been included in this chapter.
In addition, studies which have looked at cost of care in patients with COPD and
exacerbations of COPD were also reviewed here.

The studies found in the literature review were categorized as:
1. Trends in COPD-related hospitalizations and mortality.
2. Factors responsible for or predictors of COPD-related hospitalizations and
mortality.
3. Costs of managing exacerbations and COPD-related hospitalizations

Trends in COPD‐related hospitalizations and mortality
Mannino and colleagues (2002) used data from national health surveys conducted
by National Center for Health Statistics (NCHS) to report trends in different measures of
COPD during 1971-2000. The results in the COPD surveillance summary report showed
that during 2000, COPD was responsible for 726,000 hospitalizations and 119,000
deaths. The most substantial change was an increase in the mortality rate due to COPD
in women; from 20.1/100,000 in 1980 to 56.7/100,000 in 2000. There was a more
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modest increase in the mortality rate for men; from 73.0/100,000 in 1980 to 82.6/100,000
in 2000. Also in 2000, the number of women dying from COPD exceeded the number of
men for the first time. During the study period, the overall death rate for COPD
increased 67%. The results also showed that the hospitalization rates for COPD among
Caucasians were greater than those among African Americans during 1980-1987, after
which rates have been similar. Hospitalization rates for men were greater than females
through 1980s; however, since 1995, these rates have been similar. Since 1990,
hospitalization for COPD have increased among all age groups, with the largest increase
observed for those aged 65-74 years (62%) and those ≥75 years (52%).28
Saynajakangas and colleagues (2004) conducted a retrospective study to assess
the trends in the duration of inpatient episodes following emergency admissions for
COPD. The hospital discharge register maintained by the Finnish National Research and
Development Center for Welfare was investigated. Records of emergency admissions of
patients aged over 44 years (n = 72,672) that ended during 1993-2001 and had COPD as
the principal diagnosis were included in the analysis. The results showed that the mean
age on admission was 72.1 years (SD 8.7) in 2001. The average hospital LOS was 7.8
days (SD 7.6), being 8.5 days (SD 8.2) in 1993 and 6.8 days (SD 6.6) in 2001, indicating
a decrease in LOS for COPD exacerbations. Elderly women (aged 64 years and older)
had the longest inpatient episodes (LOS = 8.8 days). A total of 12.1% of the patients had
10 or more inpatient episodes. It was also reported that a 1-week stay in hospital resulted
in the longest interval to readmission.29
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Predictors of COPD‐related hospitalizations
McGhan and colleagues (2007) used the Veteran’s Affair health-care system to
determine the predictors of rehospitalization and mortality rates in patients with COPD.
They used data for inpatient stays; and a sample of 51,353 patients was included in the
study.

Only those, who were hospitalized for COPD and discharged between years

1999-2003, were included in the study. The two primary outcomes that were studied
were time to death and time to death in the time frame of six years. The study results
showed that the majority of patients (63%) had a history of prior hospitalization, and a
history of non-COPD hospitalization was more common than a history of hospitalization
for COPD. Many patients had multiple subsequent stays for COPD, with a mean LOS of
6.5 days. The risk of rehospitalization for COPD was 25% at 1 year, and 44% at 5 years.
The risk of mortality was found to be considerable in the cohort, with the risk of death
21% at 1 year, and 55% at 5 years. Increasing age, being male, number of prior
hospitalizations, and certain comorbidities including asthma and pulmonary hypertension
were found to be risk factors for death and rehospitalization in patients discharged after a
severe exacerbation. Noncaucasian race and other comorbidities were associated with a
decreased risk.30

Chen and colleagues (2005) used the Person Orientated Information Database,
which contains the hospital discharge data from all Canadian provinces in a retrospective
cohort study. Participants included 257,604 COPD patients in the 3-year study period
(1994-1997). The results showed 142,770 hospitalizations due to COPD as primary
diagnosis, and 463,089 hospitalizations for COPD listed as one of the five underlying
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diagnosis. Overall, men were more likely to have hospitalizations for COPD and had a
higher proportion of death at hospital than women. The relative risk for women versus
men gradually increased with decreasing age, and was significantly greater in the 55-59
year group for hospitalizations due to COPD as a primary diagnosis. The researchers
also believed that there was a growing body of evidence for a possibility of increased
susceptibility to COPD in response to tobacco smoke in women.31

Prescott and colleagues (1997) examined data from the Copenhagen City Heart
Study (CCHS). The subjects were administered a questionnaire assessing their level of
education, household income, tobacco consumption, pulmonary symptoms, and
measurement of lung function by spirometry. The results indicated that socio-economic
status, measured by income and educational level, is significantly associated with
admission to hospital for COPD. The age adjusted relative risks of admission to hospital
for COPD, in the lowest socioeconomic group was approximately three-fold higher than
in the highest group, and was similar in females and males. The study results indicated
that socioeconomic factors affected the adult risk of developing COPD, independently of
smoking status in both females and males.32

Holguin and colleagues (2005) used the National Hospital Discharge Survey data
(1979 to 2001); to study the prevalence of co-morbidities and in-hospital mortality of
patients with COPD. During the study period, there were an estimated 47,404,700
hospital discharges; of which 20.8% had COPD as the primary diagnosis, and 79.2 % had
COPD as a secondary diagnosis. It was concluded that any mention of COPD in the
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discharge diagnosis is associated with higher hospitalization prevalence and in-hospital
mortalities.17

Ansari and colleagues (2007) computed age- and gender-standardized hospital
admission rates of COPD for years 2003-2004 in Australia, using the Victorian Admitted
Episodes Dataset. Hospital admission rates for COPD were found to be higher in rural
areas of Victoria than in metropolitan areas. Multiple regression analysis showed
significant association between COPD admission rates and socio-economic status,
smoking rates, and remoteness of area.33

An audit study of acute hospital care of COPD was conducted in the UK by
Hosker and colleagues (2007). The audit was run jointly by the Clinical Effectiveness
and Evaluation unit of the Royal College of Physicians and the British Thoracic Society.
The audit showed that, despite the publication of standards and guidelines for the
management of COPD, there remained marked between-hospital variability in all aspects
of acute inpatient COPD care. The type and severity of patients admitted to large,
medium, and small units were similar, but the organization and facilities available for
those patients were not. In addition, the process of care and outcomes appeared worse in
smaller hospitals.34

The results of another pilot study conducted by Roberts et al (2003) in England
and Wales also showed that better survival was seen in teaching and larger hospitals;
suggesting that significant differences in mortality in acute COPD may exist between
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hospital types. Thirty hospitals were randomly selected by geographical region and
hospital types (teaching, large and small district general hospital [DGH]). Data on
process and outcomes of care including death and LOS was collected, both
retrospectively and prospectively. Small DGHs were seen to have a higher mortality
(17.5%) than teaching hospitals (11.9%) and large DGHs (11.2%).35

Cost of exacerbations and hospitalizations
Some studies show that the cost of hospital stay represents 40-57% of the total
direct costs generated by patients with COPD, reaching as high as 63% in severe patients.
28, 29

Miravitlles and colleagues (2003) conducted a prospective one-year follow-up study

on a large cohort of patients (n = 1,510) with chronic bronchitis and COPD, recruited
from general practices located throughout Spain. All direct medical costs incurred by the
cohort and related to their respiratory disease were reviewed. They reported that the
mean direct annual cost of chronic bronchitis and COPD was $1,876, and hospitalization
costs represented 43.8% of these costs. The cost of severe COPD ($2,911) was almost
double that of mild COPD ($1,484). Hospitalization accounted for 41.2% and 46.8% of
the total costs for mild COPD and severe COPD respectively. They also reported that the
cost of chronic bronchitis and COPD were almost twofold of those reported for asthma.27

Hilleman and colleagues (2000) used a retrospective study design in a university
teaching hospital setting. A cost of illness analysis was conducted using health-care
resource utilization data and costs identified through chart review. Severity of COPD
was stratified using the American Thoracic Society stages I, II, and III. The study
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demonstrated a strong correlation between disease severity and total treatment cost in
COPD, with stage I having the lowest cost. The study also demonstrated that the type of
bronchodilator therapy also impacts total cost in COPD. Hospitalization was the most
important cost variable for all three stages of COPD severity. The study results
supported the notion that adherence to published treatment guidelines in COPD resulted
in lower health-care costs.14 The annual median treatment costs per patient per year
across different stages of COPD were as follows: (See Table 2)

Wilson and colleagues (2000) used a prevalence approach and a societal perspective to
estimate the annual direct medical costs of COPD (specifically chronic bronchitis and
emphysema) in 1996, in the US. The authors used multiple national, state, and local data
sources to estimate the health-care utilization and costs. The annual direct medical costs
of COPD were $14.5 billion in 1996 dollars. Total inpatient costs were $8.3 billion (57%
of total costs) while outpatient and emergency care were $5.8 billion (40% of total costs),
and home and institutional care was only $0.34 billion. The largest costs were for
inpatient hospital stays ($7.8 billion, 54% of total costs).36 Hospital inpatient utilization
and costs by disease (chronic bronchitis and emphysema) in 1996, are indicated in Table
3.
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Table 2: Annual median treatment costs incurred over the entire duration of followup and stratified by severity of COPD.
Hospitalization cost*

Severity of COPD

Total cost

Stage I

$680 (40%)

$1,681

Stage II

$2,658 (53%)

$5,037

Stage III

$6,770 (63%)

$10,812

Hilleman and colleagues (2000)
*Costs presented as per patient per year (percentage of total costs)

Table 3: Hospital utilization and related costs, by disease.
Disease

No. of discharge
(in thousands)

Length of stay
(in days)

Hospitalization

Total costs

rate (%)

(in billions)

COPD

1,465

7.06

8.93%

8.3

CB

1,168

6.97

8.15%

6.3

296

7.92

14.3%

2.0

Emphysema

Wilson and colleagues (2000)
COPD= Chronic Obstructive Pulmonary Disease.
CB= Chronic Bronchitis
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In another study of COPD-related costs, Sullivan and colleagues (2000) studied
the National Medical Expenditure Survey and indicated that inpatient hospitalization and
emergency department care formed the largest proportion (72.8%) of total expenditure.
Only 10% of persons with COPD accounted for more than 70% of all medical care costs.
The study also reported that international studies of trends in COPD-related
hospitalization indicated that although the average LOS had decreased since 1972,
admissions per 1,000 persons per year for COPD had increased in all age groups 45
years and older.37

Health-care utilization is usually significantly increased during an exacerbation
and thus, exacerbations are considered the key drivers of costs in COPD.38
Miravitlles and colleagues (2002) conducted pharmacoeconomic evaluation of
acute exacerbations of chronic bronchitis and COPD using a prospective study design in
an ambulatory setting, in Spain. The study results showed that the total direct mean cost
of all exacerbations was $159, and patients who were hospitalized generated 58% of the
total cost. Cost per treatment failure, defined as the need of a new medical contact for
persistence or aggravation of symptoms during the 30 days after initiating treatment, was
$477.50. Thus, 63% of the total costs associated with the management of exacerbation
were costs derived from treatment failure. Sensitivity analysis showed that, when
treatment failure is reduced to zero, the average cost of treatment of an exacerbation
would decrease from $159 to only $58.7.4
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Although, there is a body of literature which reflect on the differences in
outcomes for respiratory diseases, such as asthma and lung cancer; there is very little
information about disparities in COPD care.39 Several patient characteristics like age,
gender, race, comorbidities, disease severity, and prior hospitalizations have been
identified as predictors of outcomes like LOS, in-hospital mortality, and total costs in
hospitalizations due to COPD. Some correlation between the hospital characteristics
such as hospital type and location, and the outcomes, was also seen. However, no study
has been conducted that gives a detailed overview of disparities among patients with
COPD, based on the patient and hospital characteristics; at a national level. Also, it has
not been studied whether patient’s type of insurance or their socioeconomic status (SES)
can be one of the predictors of hospital LOS, mortality, and the total costs of
hospitalization in patients with COPD. The present study aims to retrospectively
determine hospital LOS, mortality, total hospital charges, and trends in these outcomes;
in patients hospitalized with COPD. A descriptive analysis of different patient- and
hospital-related characteristics that affect these outcomes using the Nationwide Inpatient
Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP) data will be
conducted.
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CHAPTER THREE
METHODOLOGY
Data Source
Healthcare Cost and Utilization Project (HCUP)
The HCUP is a family of health care databases and related software tools
developed through a Federal-State-Industry partnership to build a multi-state health data
system for health care research and decision-making. The HCUP sponsored by the
Agency for Healthcare Research and Quality (AHRQ), contains a core set of clinical and
nonclinical information found in a typical discharge abstract. The information is
translated into a uniform format with privacy protections in place. HCUP includes the
largest collection of longitudinal hospital care data in the US, with all-payer, encounterlevel information beginning in 1988. The HCUP databases enable research in different
areas such as health policy issues, including cost and quality of health services, medical
practice patterns, access to health care programs, and outcomes of treatments at the
national, state, and local market levels.
The Nationwide Inpatient Sample (NIS), one of the datasets of HCUP, was used
in this study. The NIS is the largest all-payer inpatient dataset that includes information
on all discharge data from a national sample of more than 1,000 hospitals. All discharges
from sampled hospitals are included in the NIS database. The NIS is available from 1988
to 2005. It is the only national hospital database with charge information on all patients,
regardless of payer, including persons covered by Medicare, Medicaid, private insurance
and the uninsured. Inpatient stay records in the NIS include patient-level clinical and
resource use information included in a typical discharge abstract. Hospital and discharge
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weights are provided for producing national estimates. The NIS contains discharge-level
records, not patient-level records. Thus, individual patients who are hospitalized multiple
times in one year may be present in the NIS multiple times. There is no uniform patient
identifier available that allows a patient-level analysis with the NIS.
The NIS is designed to approximate a 20% stratified sample of US community
hospitals. The American Hospital Association (AHA) defines community hospital as “all
non-federal, short term, general and other specialty hospitals, excluding hospital units of
institutions.” The NIS includes specialty hospitals such as obstetrics-gynecology, earnose-throat, short term rehabilitation, orthopedic, pediatric, public hospitals and academic
medical centers. Excluded are long term hospitals, psychiatric hospitals,
alcoholism/chemical dependency treatment and short term rehabilitation (beginning with
1998 data). The community hospitals are divided into strata using five hospital
characteristics: ownership/control, bed size, teaching status, urban/rural location and US
region. Researchers and policymakers use the NIS to identify, track, and analyze national
trends in healthcare utilization, access, charges, quality and outcomes.
From the NIS dataset for each year, the inpatient core data file was utilized. This
inpatient discharge-level file contains data for 100% of the discharges from a sample of
hospitals in participating states, and the unit of observation is an inpatient stay record. To
address some of the objectives, the hospital weights file was also used from the NIS
dataset. It contains weights and variance estimation data elements, as well as linkage
data elements, and the unit of observation is the hospital. Data elements from both these
files were used to create a final dataset, to be used for analysis in this study. The
summary for the NIS datasets used in the study are given in Table 4.
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Table 4: Summary of NIS datasets
Year

Data from

Number
of hospitals

Number of
discharges,
unweighed

Number of
discharges,
weighed for
national estimates

2002

35 states

995

7,853,982

37,804,021

2003

37 states

994

7,977,728

38,220,659

2004

37 states

1,004

8,004,571

38,661,786

2005

37 states

1,054

7,995,048

39,163,834

Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcupus.ahrq.gov
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The NIS contains several clinical and non-clinical data elements for each hospital
stay. Data elements in the NIS Inpatient Core file include admission and discharge
information, patient demographics (e.g., gender, age, race, median household income for
ZIP code, location), diagnoses information, procedure information, expected payment
source, total hospital charges, length of stay (LOS), and hospital information (e.g. the
HCUP hospital identification number which provides the linkage between the NIS
Inpatient Core files and the Hospital Weights file). The NIS Hospital Weights file
contains data elements which include discharge weights (which can be used to create
national estimates), the HCUP hospital identifiers, and hospital characteristics (bed size,
location, teaching status, region.

Patient population
The NIS from HCUP for the years 2002, 2003, 2004 and 2005 were used. The
NIS data obtained from HCUP was extracted and the Inpatient Core discharge-level files
containing 100% of the discharges from a sample of hospitals in participating states were
used. The Hospital Weights file, which helps to account for the complex sampling frame
of the NIS dataset, was used. The Cost-charge ratio file, which helps to translate the
hospital charges in the dataset into actual costs, was also used. Individuals from this
sample having the primary or secondary diagnosis as COPD (as defined by the
International Classification of Diseases, 9th Revision ICD-9 code) was then selected.
Thus, all hospitalizations with primary or secondary diagnosis (only the first and the
second diagnostic listing) with ICD-9 codes 490-492 and 496 were extracted and merged,
to form our final dataset that was used for the several objectives of our study.
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Data extraction
The NIS data obtained from the HCUP was extracted by decompressing the data
and unzipping the required necessary files such as NIS Inpatient Core and Hospital
Weights files. These files which were in ASCII format were converted to Statistical
Package for Social Sciences (SPSS)(version 16.0) for analytical purposes. The
conversion of ASCII to SPSS format was done with the help of SPSS Load Programs
obtained in the NIS documentation files available on the HCUP-US website. 40 From
this main data, only individuals having COPD were selected. Individuals from this
sample having a primary or secondary diagnosis of COPD (as defined by the ICD-9 code)
were then selected. This dataset was used as the final dataset for the several objectives of
this study. The same extraction procedure was applied to all datasets for each of the four
years.

Patient‐Level Variables
Patient-level variables that were included in the analysis were age, race, gender,
payer information, location of patient, and median household income. These variables
were described by the NIS as:
Age at admission
Age at admission, was coded 0-124 years in HCUP. Age at admission was
calculated from the date of birth and the admission date. It was considered invalid if it
was out of range (0-124 years) or it could not be calculated. For the purpose of our
analysis, age was categorized in different age groups: 0-20 years, 21-40 years, 41-64
years, 65-80 years, and 80 years and above. These levels of age were categorized to
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reflect access to Medicare (starting after age 65).

Race
Both race and ethnicity are included in one data element as ‘Race’ in HCUP. In
HCUP, the variable race is categorized into Caucasian, African American, Hispanic,
Asian or Pacific Islander, Native American, and others. For regression analyses in our
study, race was categorized into the following four groups: Caucasian, African American,
Hispanic and Others.

Gender
The gender variable was used as an indicator of sex of the hospitalized patient.

Payer information
The payer variable indicates the expected primary payer. In HCUP, to ensure the
uniformity of coding across data sources, this variable combines detailed categories in the
more general groups like Medicare, Medicaid, Private insurance, self pay, no charge and

other. For example, Medicare includes both fee-for-service and managed care Medicare
patients. Medicaid too includes both fee-for-service and managed care Medicaid
patients. Private insurance includes Blue Cross, Commercial carriers, and private health
maintenance organizations (HMOs) and preferred provider organization (PPOs). Other
includes Worker’s compensation, The Civilian Health and Medical Program of the
Uniformed Services (CHAMPUS), The Civilian Health and Medical Program of the
Department of Veterans Affairs (CHAMPVA), and other government programs.
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Patient Location
The patient location variable is a four category urban-rural designation for the
patient’s county of residence. The 12 categories of the Urban Influence Codes (UIC) are
combined into four broader categories: large metropolitan areas with at least 1 million

residents, small metropolitan areas with less than 1 million residents, micropolitan areas
(non-metro areas either adjacent to large metro or small metro or not adjacent to any
metro area), and non-urban areas (non-core areas either adjacent or not adjacent to a
metro or a micro).

Median household income
This variable is the median household income for patient’s ZIP code (based on
current year) and provides a quartile classification of the estimated median household
income of residents in the patient’s ZIP code. Quartiles are identified by the values of 1
to 4 indicating poorest to the wealthiest population. Since these estimates are updated
annually, the value ranges vary by year. Dollar ranges represented by each category are
shown in Table 5.
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Table 5: Levels of median household income quartiles for patient’s ZIP codes. NIS
2002‐2005
Year

Quartile 1($)

Quartile 2 ($)

Quartile 3 ($)

Quartile 4 ($)

2002

1-35,999

36,000-45,999

46,000-61,999

≥ 62,000

2003

1-35,999

36,000-45,999

46,000-59,999

≥ 60,000

2004

1-35,999

36,000-45,999

46,000-58,999

≥ 59,000

2005

1-36,999

37,000-45,999

46,000-60,999

≥ 61,000

Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcupus.ahrq.gov
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Hospital‐Level Variables

Hospital-level variables such as geographic region, location, teaching status, and
hospital bed size were utilized for the purpose of the study. These variables were
obtained from the NIS Hospital Weights file, and the HCUP hospital identification
number was used to provide the linkage between the NIS Inpatient Core files and the
Hospital Weights file.
In NIS, the NIS Stratum is a four-digit stratum identifier used to post-stratify
hospitals for the calculation of universe and frame weights. The NIS Stratum includes the

hospital census region, ownership/control, location/teaching status, and bed-size; all
combined into one variable. Information on the hospital variables was obtained from the
American Hospital Association (AHA) Annual Survey of Hospitals. For the purpose of
analysis in this study, the hospital level variables were looked at separately:

Geographic region
The hospital's geographic region was classified into four categories: Northeast,
Midwest, South, and West. This information was obtained from the AHA Annual Survey
of Hospitals, and the geographic region was defined by the U.S. Census Bureau. This is
an important stratifier because practice patterns have been shown to vary substantially by
region. For example, lengths of stay tend to be longer in East Coast hospitals than in
West Coast hospitals.40
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Table 6: All states by Region, NIS 2005
Region
Northeast

States
Connecticut, Maine, Massachusetts, New Hampshire, New Jersey,
New York, Pennsylvania, Rhode Island, Vermont.

Midwest

Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri,
Nebraska, North Dakota, Ohio, South Dakota, Wisconsin.

South

Alabama, Arkansas, Delaware, District of Columbia, Florida,
Georgia, Kentucky, Louisiana, Maryland, Mississippi, North
Carolina, Oklahoma, South Carolina, Tennessee, Texas,
West-Virginia.

West

Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana,
Nevada, New Mexico, Oregon, Utah, Washington, Wyoming.

Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcupus.ahrq.gov

41

Location
The hospital location is categorized as rural and urban. Beginning with the 2004 data,
the classification of urban or rural hospital location used the newer Core Based Statistical
Area (CBSA) codes. CBSA groups were based on 2000 Census data. Hospitals residing in
counties with a CBSA type of metropolitan were considered urban, while hospitals with a
CBSA type of micropolitan or non-core were classified as rural. Government payment
policies often differ according to this designation. Also, rural hospitals are generally smaller
and offer fewer services than urban hospitals.

Teaching status

The hospital's teaching status was obtained from the AHA Annual Survey of
Hospitals. The missions of teaching hospitals differ from nonteaching hospitals. In
addition, financial considerations differ between these two hospital groups. A hospital is
considered to be a teaching hospital if it has an AMA-approved residency program, is a
member of the Council of Teaching Hospitals (COTH) or has a ratio of full-time
equivalent interns and residents to beds of .25 or higher.
Rural hospitals were not split according to teaching status, because rural teaching
hospitals were rare.

Bed-size
Bed-size categories are based on hospital beds, and bed-size assesses the number of
short-term acute beds in a hospital. Hospitals were classified on the basis of bed size as

small, medium and large. Refer Table 7. The hospital's bed-size category is nested within
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location and teaching status, and is defined using region of the U.S, the urban-rural
designation of the hospital, in addition to the teaching status.

Table 7: Hospital bed size categories, by region. NIS 2005
Location & Teaching status

Hospital bed-size
Small

Medium

Large

Rural

1-49

50-99

100+

Urban, Non-Teaching

1-124

125-199

200+

Teaching

1-249

250-424

425+

Rural

1-29

30-49

50+

Urban, Non-Teaching

1-74

75-174

175+

Teaching

1-249

250-374

375+

Rural

1-39

40-74

75+

Urban, Non-Teaching

1-99

100-199

200+

Teaching

1-249

250-449

450+

Rural

1-24

25-44

45+

Urban, Non-Teaching

1-99

100-174

175+

Teaching

1-199

200-324

325+

Northeast Region

Midwest Region

Southern Region

Western Region

Adapted from Introduction to the HCUP NIS, available on the HCUP-US website http://www.hcupus.ahrq.gov
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Other Variables related to Diagnoses, Procedures and Type of admission
Other variables which can affect the patient’s hospital resource utilization, such as
variables related to the diagnosis reported or procedures conducted were also considered
in the analysis.

Number of procedures
The Number of Procedures (NPR) variable indicates the total number of ICD-9CM procedures coded on the discharge record. A maximum of 15 procedures have been
retained on a NIS inpatient record. Some states provided fewer than 15 procedures on the
discharge record; for example, if a state supplied 5 procedures, PR6 through PR15 are
blank (" ") on all records from that state. Whereas some states provide more than 15
procedures, and these records may have information truncated. If an inpatient record
from these states had more than 15 non-missing procedures, procedures in positions 16
and above was not included in the NIS file.

Number of diagnoses on discharge record
The Number of Diagnoses (NDX) variable indicates the total number of
diagnoses coded on the discharge record. Similar to NPR, a maximum of 15 diagnoses
has been retained on a NIS inpatient record. States that provide more than 15 diagnoses
may have information truncated for this variable.

Elective
The ELECTIVE variable indicated, whether the admission to the hospital was
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elective or non-elective. This information was derived from another variable related to
type of admission (ATYPE).
Outcome Variables
The outcome variables that were included in this study were hospital length of
stay (LOS), in-hospital deaths, total hospital costs, and principal procedures performed on
a patient with COPD. The total hospital charges were obtained from the Inpatient Core
files and the Cost-to-Charge Ratio files were used to convert the charge data, and derive
cost estimates of in-patient care. Following is the information on these variables as
provided by HCUP.

Length of stay (LOS)
LOS is calculated by subtracting admission date from the discharge date. Same
day stays are hence coded as 0. The value of LOS ranges from 0-365 days.

In-hospital death
This indicates whether the patient died during hospitalization. It is coded from
disposition of the patient, depending on whether the patient was discharged alive or if the
patient died in the hospital.

Total hospital charge/costs
The total hospital charge variable provides the value of a total hospital charge for
a patient. The total charge is rounded to the nearest possible figure, and the value of this
variable ranges from US $25 – $1 million. Generally total charges in HCUP do not
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include professional fees and non-covered charges. If the source provides total charges
with professional fees, then the professional fees are removed from the charge during HCUP
processing. But emergency department charges incurred prior to admission to the hospital

may have been included in total hospital charges. Then total hospital costs were
computed for each discharge record using the Cost-to-charge ratio to convert the charges
to costs.

Data Analysis
The data analysis was conducted by using SPSS (version 16.0). The first eight
objectives of this study were analyzed using the NIS dataset for the year 2005. For
studying trends in LOS, total hospital costs, and the procedures (Objectives 9), datasets
for 2002-2005 were utilized.

Objective 1: To calculate weighed averages for COPD‐related hospitalizations,
annual inpatient deaths and mean total charges for the year 2005.
Hospital and discharge weights were used to generate national level weighed
averages for total number of cases with a primary or secondary diagnosis of COPD, and
annual inpatient deaths and mean total charges and costs due to COPD-related
hospitalizations.

Objective 2: To describe the COPD‐related hospitalizations in the core in‐patient
sample from the NIS from HCUP dataset in terms of patient and hospital
characteristics.
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A descriptive analysis was conducted where frequencies for each of the patientand hospital-related and other related variables, were analyzed. Frequencies for LOS, inhospital deaths and total hospital charges were also analyzed and reported. Only those
patients were included in the analysis, who had a primary diagnosis of COPD.

Objective 3: To compare the differences in the COPD‐related hospital length of stay
(LOS) by patient and hospital characteristics.
Means for LOS were compared across each of the patient- and hospital-related
variables. Only those patients were included in the analysis, who had a primary diagnosis
of COPD. All patient- and hospital-related variables of interest were taken as
independent variables, whereas LOS was taken as a dependent variable. For variables
with more than two categories, one-way ANOVA was conducted to check if the different
categories of each variable differed significantly among each other. Those variables
which were observed to be significant in ANOVA were subjected to Post-hoc Hochberg
analysis. The Post-hoc analysis is helpful in isolating exactly where the significant
differences among variables lie. For a variable that had two categories (e.g., gender) a ttest was conducted to see if LOS, total hospital charges, and procedures differed between
males and females.

Objective 4: To compare the differences in COPD‐related total hospital costs by
patient and hospital characteristics.
Means for total hospital costs were compared across each patient and hospital
variable. Only those patients were included in the analysis, who had a primary diagnosis
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of COPD. Also here, one-way ANOVA, post-hoc analyses and independent t-test were
conducted to look for differences among categories.

Objective 5: To compare the differences in COPD‐related in‐hospital deaths by
patient‐ and hospital‐related characteristics.
Cross tabulations were conducted to compare proportions of in-hospital deaths
across the several patient-related and hospital-related variables. Only those patients were
included in the analysis, who had a primary diagnosis of COPD.

Objective 6: To identify patient‐ and hospital‐related predictors of COPD‐related
hospital LOS., total hospital costs and in‐hospital deaths.
A multiple linear regression model was utilized to achieve this study objective.
Only those patients were included in the analysis, which had a primary diagnosis of
COPD. All patient-related and hospital-related variables were used as independent
variables to predict LOS. While conducting the analyses, LOS was taken as the
dependent variable. Both Enter and Stepwise methods of multiple linear regressions
were utilized. Variables having a significant p-value (defined as p ≤ 0.05) were reported
as predictors for LOS. All variables having more than two categories were subject to
creation of dummy variables. Hence, dummy variables were created for age, race,
location, payer information, median household income, and all hospital-related variables.
Dummy variables are needed as they help in indicating the absence or presence of some
categorical effect that may shift the outcome of the analyses.
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Objective 7: To identify patient- and hospital-related predictors of COPD-related total
hospital costs.
Similar analysis, as described for objective 6 was conducted, and the dependent
variable here was total hospital costs.

Objective 8: To identify patient- and hospital-related predictors of COPD-related inhospital deaths
Similar analysis, as described for objective 6 was conducted; however Binary
logistic regression was used instead of multiple linear regression. The dependent variable
here was in-hospital mortality.

Objective 9: To describe the temporal pattern of COPD‐related hospitalization LOS,
total hospital costs and in‐hospital deaths for 2002, 2003, 2004, and 2005 using the
core in‐patient sample from the NIS from HCUP dataset.
Descriptive statistics were conducted to check for the frequencies of LOS, total
hospital costs and the number of in-hospital deaths for the years 2002, 2003, 2004, and
2005. Only those patients were included in the analysis, who had a primary diagnosis of
COPD. Means for LOS were reported, and a temporal pattern (trend) if observed, was
also reported. Hospital costs were adjusted to the year 2005 (last quarter) levels, using
the consumer price index for inpatient hospital services that were provided by the Bureau
of Labor Statistics.
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CHAPTER FOUR
RESULTS
In this chapter, results for the study objectives will be presented.

From the NIS dataset for each year, the inpatient discharge-level data representing
100% of the discharges from a sample of hospitals in participating states was utilized.
From this main data, only individuals having COPD as primary or secondary diagnosis,
based on the ICD-9 codes (490.xx-492.xx and 496.xx) were then selected. For study
objectives 1 through 8, NIS dataset for year 2005 was utilized, while for study objective 9
which described the trends, NIS datasets for years 2002-2005 were utilized. For all the
analysis, hospitalizations due to COPD as primary diagnosis only were considered;
except for study objective 1, where hospitalizations due to COPD as secondary diagnosis
were also considered. There were 126,504; 127,393; 112,983 and 126,130
hospitalizations identified with COPD as the primary diagnosis in the datasets for years
2002, 2003, 2004, and 2005 respectively.

Objective 1: National estimates for hospital LOS, mean total charges, and
in‐hospital mortality for hospitalizations due to COPD for the year 2005
Using the 2005 data, descriptive analysis were conducted to determine the
frequencies of total hospitalizations, mean LOS, mean total charges, in-hospital deaths
with COPD as both a primary and secondary diagnosis. Discharge weights were applied
to derive weighed averages or national estimates. There were 616,818 estimated
hospitalizations in the year 2005 with COPD as the primary diagnosis. Additionally an
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estimated 1,426,723 hospitalizations were identified, with COPD as the secondary
diagnosis on record. Both the mean LOS and the mean total charges and costs were
higher for records with COPD listed as a secondary diagnosis. After applying weights,
the mean LOS and mean total costs for hospitalizations with COPD as primary diagnosis
were found to be 4.86 and $6,938.55; whereas for hospitalizations with COPD as
secondary diagnosis, they were 5.03 and $7,636.73, respectively. There were an
estimated 12,054 in-hospital deaths due to COPD as primary diagnosis and an estimated
40,738 in-hospital deaths due to COPD as secondary diagnosis in the year 2005.
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Table 8. National estimates (Weighed data) of COPD ‐ related hospitalizations:
NIS 2005

Variable

Diagnosis of COPD
Primary

Secondary

Hospitalizations

616,818#

1,426,723#

Deaths

12,054#

40,738#

LOS

4.68 ± 3.62*

5.03 ± 4.24*

Total hospital charges ($)

17,259.84 ± 21,660.84*

23,450.62 ± 27,784.86*

Estimated Costs ($)

6,938.55 ± 7,776.81*

7,636.73 ± 8,250.43*

*Mean ± S.D
#Total Number
LOS = Length of stay
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Objective 2: Frequency of patient, hospital, and outcome variables
Using descriptive analysis, frequencies of patient-related, hospital-related, and
outcome variables for the year 2005 were determined. Patient variables included age,
race, gender, payer information, location and median household income. Hospital
variables included geographic region, location, and hospital bed-size. Other variables
included type of admission (elective vs. non-elective), total number of diagnoses on
record, total number of procedures on record while outcome variables included length of
stay, total hospital charges, and in-hospital mortality.

Patient variables
A descriptive analysis indicated that the study sample consisted predominantly
females (55.9%), and that the mean age of patients hospitalized with COPD in this
sample was 68.83 years (S.D. = 13.34). Caucasians (85.5%) formed a predominant
section of the patient population, followed by African Americans (7.4%) and Hispanics
(4.7%). Other races including Asians or Pacific Islanders and Native Americans,
together accounted for the least number of hospitalizations due to COPD (2.5%). The
patients were mainly located in the large metropolitan areas (44.0%), while only a small
section (13.1%) located in the non-core areas. A majority of the patients (33.9%) were in
the income level group of $1- $36,999 followed by the group with income level $37,000$45,999 (28.3%). The primary expected payer for most of the patient population was
Medicare (71.9%) followed by private payers (13.9%) and Medicaid (9.3%). (Refer
Table 9)
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Table 9. Patient characteristics of COPD ‐ related hospitalizations: NIS 2005
(N = 125,584)
Patient variables

Level of patient variables

Age (years)

0-20

(68.83 ± 13.31)*

21-40

1,851 (1.5)

41-64

39,895 (31.8)

65-80

59,133 (47.1)

81 and above

23,885 (19.0)

796 (0.6)

Total
Race

Gender

N (%)

125,560 (100.0)

Caucasian

76,123 (85.5)

African American

6,573 (7.4)

Hispanic

4,156 (4.7)

Asian

741 (0.8)

Native American

257 (0.3)

Other

1,214 (1.4)

Total

89,064 (100.0)

Male

55,381 (44.1)

Female

70,140 (55.9)

Total

125,521 (100.0)

`
Payer

Medicare

90,248 (71.9)

Medicaid

11,653 (9.3)

Private

17,497 (13.9)

Self Pay

3,300 (2.6)

No charge

410 (0.3)

Other

2,386 (1.9)

Total

125,494 (100.0)
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Patient variables

Level of patient variables

Patient Location

Large Metropolitan

55,109 (44.0)

Small Metropolitan

34,865 (27.8)

Micropolitan

18,901 (15.1)

Non-urban

16,440 (13.1)

Total
Income

N (%)

125,315 (100.0)

$1-$36,999

41,500 (33.9)

$37,000 – $45,999

34,705 (28.3)

$46,000 – $60,999

27,167 (22.2)

$61,000 +

19,116 (15.6)

Total

122,488 (100.0)

*Mean ± S.D.
N = Number of hospitalizations at each level
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Hospital variables
The hospital located in the Southern region (45.9%) of the U.S., and urban nonteaching setting (50.9%) accounted for a majority of the hospitalizations. Very few
(13.0%) hospitalizations were seen in the Western regions of the U.S. Also, a majority of
hospitalizations were observed in hospitals with a large bed size (56.1%), with the least
number (16.9%) of hospitalizations occurring in hospitals with a small bed size(Refer
Table 10).
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Table 10. Hospital characteristics of COPD ‐ related hospitalizations: NIS 2005
(N= 125,584)
Hospital variables

Level of hospital variables

Geographic Region

Northeast

22,411 (17.8)

Midwest

29,184 (23.2)

South

57,697 (45.9)

West

16,292 (13.0)

Total

125,584 (100.0)

Rural

31,654 (25.2)

Urban non-teaching

63,979 (50.9)

Urban teaching

29,951 (23.8)

Location

Bed-Size

N (%)

Total

125,584 (100.0)

Small

21,246 (16.9)

Medium

33,898 (27.0)

Large

70,440 (56.1)

Total

125,584 (100.0)

N = Number of hospitalizations at each level
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Other procedure and diagnoses‐related variables
Most (21.8%) hospitalization records had at least 9 diagnoses listed on them,
while very few (1.3%) had only one diagnoses listed. The mean number of diagnoses
listed on record were 7.29 (S.D = 3.14). In terms of number of procedures on record,
majority of the records (78%) had no procedures listed, whereas only 11.4% records
showed at least one procedure to be listed on the record. Most (89.2%) of the
hospitalizations were due to non-elective admissions (Refer Table 11).
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Table 11. Other characteristics of COPD ‐ related hospitalizations: NIS 2005
(N= 125,584)
Variables

Level of variables

Number of diagnoses

1

1,589 (1.3)

on the record

2

4,428 (3.5)

(7.29 ± 3.14)*

3

8,010 (6.4)

4

10,971 (8.7)

5

13,287 (10.6)

6

13,697 (10.9)

7

2,772 (10.2)

8

2,493 (9.9)

9

27,391 (21.8)

10 and above

20,926 (16.3)

Total

N (%)

125,584 (100.0)

Number of procedures

0

97,910 (78.0)

on the record

1

14,307 (11.4)

(0.45 ± 1.14)*

2

6,212 (4.9)

3

3,319 (2.6)

4

1,622 (1.3)

5

884 (0.7)

6

755 (0.6)

7

213 (0.2)

8

135 (0.1)

9

100 (0.1)

10 and above

127 (0.1)

Total

125,584 (100.0)
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Variables

Level of variables

Type of hospital

Elective

admission

Non-elective

N (%)
13,271 (10.6)
111,995 (89.2)

Total

125,266 (100.0)

* Mean ± S.D.
N = Number of hospitalizations at each level
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Table 12. Top five Secondary Diagnoses listed on records of patient with a Primary
diagnosis of COPD: NIS 2005 (N= 125,584)
ICD-9 Code

Disease/ Illness

N (%)

428.0

Congestive heart failure, unspecified

15,735 (12.5)

401.9

Essential hypertension, unspecified

7,863 (6.3)

427.31

Atrial fibrillation

6,971 (5.6)

486.0

Pneumonia

4,611 (3.7)

305.1

Tobacco use disorder

3,626 (2.9)
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Table 13. Top five Primary Diagnoses listed on records of patient with a Secondary
diagnosis of COPD: NIS 2005 (N= 288,992)
ICD-9 Code

Disease/ Illness

N (%)

486.0

Pneumonia

210,669 (14.8)

428.0

Congestive heart failure, unspecified

119,560 (8.4)

518.81

Acute respiratory failure

786.59

Chest pain

29,843 (2.1)

414.01

Coronary arthrosclerosis

29,690 (2.1)
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62,264 (4.4)

Outcome variables
It was seen that LOS for patients hospitalized with COPD ranged from 0-102
days. However, to exclude extreme outliers, only those records with LOS ≤ 30 days were
considered for analysis, and the mean LOS was found to be 4.69 days (S.D. = 3.63)
(Refer Table 14). The majority of hospitalizations (52.1%) were for 2-4 days, while only
8% patients had mean LOS of 10 or more days.
The total costs for hospitalization for COPD ranged from $29 - $311,599 with a
mean total charge of $6,939.94 (S.D=7,759.51) for the year 2005. Around 74.8% of all
hospitalizations had total charges in the range of $1,000 - $9,999; another 11.3%
hospitalizations had hospital charges in the range of $10,000 -$19,999, while only 0.5%
hospitalizations had hospital charges of more than $50,000.
A total of 2,451 in-hospital deaths due to COPD as primary diagnosis were
reported in the year 2005 (Refer Table 15).
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Table 14. Hospital length of stay (LOS), total hospital charges and costs for COPD‐
related hospitalizations: NIS 2005 (N= 125,584)
Outcome variables

Level of outcome variables

LOS (days)

0

1,193 (0.9)

(4.69 ± 3.63)*

1

10,344 (8.2)

2

22,189 (17.7)

3

23,974 (19.1)

4

19,265 (15.3)

5

13,758 (11.0)

6

9,699 (7.7)

7

7,046 (5.6)

8

4,733 (3.8)

9

3,280 (2.6)

10 & above

N (%)

10,103 (8.0)

Total

125,584 (100.0)

Total hospital charges

0-999

207 (0.2)

(dollars)

1,000-9,999

53,453 (42.9)

(17,383.78 ± 21,719.35)*

10,000-19,999

40,448 (32.5)

20,000-29,999

14,445 (11.6)

30,000-39,999

6,395 (5.1)

40,000-49,999

3,409 (2.7)

50,000-59,999

1,915 (1.5)

60,000-69,999

1,197 (1.0)

70,000-79,999

792 (0.6)

80,000-89,999

534 (0.4)

90,000-99,999

388 (0.3)

100,000 & above
Total

1,323 (1.1)
125,584 (100)

64

Outcome variables

Level of outcome variables

N (%)

Total hospital costs

0-999

(dollars)

1,000-9,999

93,897 (74.8)

(6,939.94 ± 7,759.51)*

10,000-19,999

14,149 (11.3)

20,000-29,999

2,876 (2.3)

30,000-39,999

936 (0.7)

40,000-49,999

419 (0.3)

50,000-59,999

195 (0.2)

60,000-69,999

126 (0.1)

70,000-79,999

84 (0.1)

80,000-89,999

40 (0.0)

90,000-99,999

21 (0.0)

100,000 & above

87 (0.1)

1,019 (0.8)

Total

113,849 (100)

* Mean ± S.D.
N = Number of hospitalizations at each level
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Table 15. Deaths during hospitalization in of COPD ‐ related hospitalizations:
NIS 2005 (N = 125,584)
Levels of variable ‘Died’

N (%)

Died during hospitalization

2,451 (2.0)

Did not die during hospitalization

123,092 (98.0)

Total

125,543 (100.0)

N = Total Number
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Objective 3: Differences in length of stay (LOS) by patient‐related and hospital‐related
variables
For the year 2005, the differences in LOS were observed for patients with COPD,
by patients and hospital variables. Means for LOS were compared across all levels of
patient- and hospital- related variables.

LOS by patient‐related variables
The mean LOS was highest for the age group 81 years and above (5.03 days, S.D.
= 3.70), and lowest for age group 0-20 years (3.04 days, S.D. = 3.08). African
Americans and Hispanics had lower LOS (4.77 days, S.D. = 3.88 and 4.73 days, S.D =
3.75) as compared to Caucasians (4.81 days, S.D. = 3.79). Females were observed to
have a longer LOS (4.84 days, S.D. = 3.64) than males (4.51 days, S.D. = 3.60). The
patients with Medicare as their primary expected payer had a longer mean LOS (4.89
days, S.D. = 3.71), followed by those with private payers (4.21 days, S.D. = 3.44), while
those with no insurance had the lowest mean LOS (3.52 days, S.D. = 3.52 days, S.D. =
2.72). Patients living in the large metropolitan had a longer LOS (4.90 days, S.D. =
3.88), whereas those who lived in the non-core areas had the lowest LOS (4.16 days, S.D.
= 3.02). The mean LOS increased with the increasing levels of patient income groups.
Patients in the income group of $1- $36,999 had a shorter mean LOS (4.53 days, S.D. =
3.49) than those in the $61,000+ group (5.07 days, S.D. = 3.94).
A one-way ANOVA was conducted for all the patient variables, except gender.
All patient variables, except Race were found to be significant (p < 0.050) (Table 16). To
further tease out the differences among the levels of the significant patient variables,
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Post-hoc Hochberg analyses were conducted. The Post Hoc tables lists the different
levels of the variables in the first column, and then compares each level to every other
level to see if they are significantly different.
The different categories of age were compared, and significant differences were
seen among all the categories of age (Refer Tables 17, 18). However, the difference
between the groups 81+ years and 0-20 years was highest (the LOS was 1.9 days longer
in the age category 81+ years as compared to those in the group 0-20 years) and the
difference was least in the groups 81+ years and 65-80 years (the LOS was only 0.16
days longer in the age category 81+ as compared to those in the group 65-80 years).
There were significant differences between patients with different Payers, in almost all
the categories of Payers (Refer Table 19). The difference was highest between those with
Medicare and those patients with no insurance, with patients under Medicare observed to
have longer LOS (1.4 days more than patients with no insurance). Significant differences
were also seen among all the categories of patient location, the difference being largest
between the patient living in the large metropolitan areas and those living in the nonurban areas (Refer Table 20). The patients in the large metropolitan areas had a relatively
longer LOS (0.73 days). Inpatient median income groups, significant differences in LOS
were seen across all the levels. The most difference was seen in patients with income
$61,000 and above as compared to those with in the income group $1- $36,999, with the
former having a longer LOS (0.53 days) than the latter.
A difference in LOS between males and females was tested using Independent ttest; and the differences between males and females were found to be found to be
statistically significant (p<0.05).
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Table 16. Differences in hospital length of stay (LOS) by patient variables: NIS 2005
(N= 125,584)
Patient variables

Level of

Mean LOS

patient variables

(days)

Age (years)

0- 20

3.04

3.08

(68.83 ± 13.31)*

21- 40

3.36

2.88

41- 64

4.31

3.04

65- 80

4.87

3.72

81+

5.03

3.74

Total

4.69

3.62

Caucasian

4.81

3.79

African American

4.77

3.88

Hispanic

4.73

3.75

Other

4.95

4.42

Total

4.81

3.75

Male

4.51

3.60

Female

4.84

3.64

Medicare

4.89

3.71

Medicaid

4.21

3.43

Private

4.27

3.44

Self Pay

3.52

2.72

No charge

3.67

3.00

Other

4.19

3.21

Total

4.69

3.63

Race

Gender

Payer
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S.D.

Patient variables

Patient Location

Income ($)

Level of

Mean LOS

patient variables

(days)

Large Metropolitan

4.90

3.88

Small Metropolitan

4.71

3.61

Micropolitan

4.49

3.29

Non-urban

4.16

3.02

Total

4.69

3.63

1-36,999

4.53

3.49

37,000 – 45,999

4.62

3.53

46,000 – 60,999

4.77

3.71

61,000 +

5.07

3.94

Total

4.69

3.63

* Mean ± S.D.
LOS = Length of stay
S.D. = Standard deviation
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S.D.

Table 17. Differences between patient variables for length of stay (LOS): NIS 2005 (N=
125,584)
Patient variables

Test statistics

Sig. (p)

Age

F = 302.426a

0.000*

Race

F = 1.991a

0.113

Payer

F = 228.440

a

0.000*

Patient Location

F = 198.243a

0.000*

Income

F = 103.753a

0.000*

Gender

T-test = -16.005b

0.000*

a

One-way ANOVA
Independent t-test.
Dependent variable: LOS
*Significance is at 0.05 level
b
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Table 18. Differences within significant patient variable (age) for length of stay (LOS):
NIS 2005 (N= 125,584)
Age (I)

Age (J)

0-20 years

21-40 years

41-64 years

65-80 years

81+ years

Mean Difference

Std. Error

21-40 years

-0.319

0.153

0.235

41-64 years

-1.274

0.129

0.042*

65-80 years

-1.830

0.129

0.000*

81+ years

-1.992

0.130

0.000*

0-20 years

0.319

0.153

0.253

41-64 years

-0.955

0.086

0.000*

65-80 years

-1.511

0.085

0.000*

81+ years

-1.673

0.087

0.000*

0-20 years

1.274

0.129

0.000*

21-40 years

0.955

0.086

0.000*

65-80 years

-0.556

0.023

0.000*

81+ years

-0.718

0.030

0.000*

0-20 years

1.830

0.129

0.000*

21-40 years

1.511

0.085

0.000*

41-64 years

0.556

0.023

0.000*

81+ years

-0.162

0.028

0.000*

0-20 years

1.992

0.130

0.000*

21-40 years

1.673

0.087

0.000*

41-64 years

0.718

0.030

0.000*

65-80 years

0.162

0.028

0.000*

Post-hoc Hochberg Analysis
Significant patient variable – Age
*Significance is at the 0.05 level
Mean Difference = I – J
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Sig. (p)

Table 19. Differences within significant patient variable (payer) for length of stay
(LOS): NIS 2005 (N= 125,584)
Payer (I)

Payer (J)

Mean Difference

Std. Error

Sig. (p)

Medicare

Medicaid

0.680

0.036

0.000*

Private

0.618

0.030

0.000*

Self Pay

1.372

0.064

0.000*

No charge

1.221

0.179

0.000*

Other

0.705

0.075

0.000*

Medicare

-0.680

0.036

0.000*

Private

-0.061

0.043

0.912

Self Pay

0.693

0.071

0.000*

No Charge

0.542

0.182

0.000*

Other

0.025

0.081

1.000

Medicare

-0.618

0.030

0.000*

Medicaid

0.061

0.043

0.912

Self Pay

0.754

0.069

0.000*

No Charge

0.603

0.181

0.000*

Other

0.087

0.079

0.990

Medicare

-1.372

0.064

0.000*

Medicaid

-0.693

0.071

0.000*

Private

-0.754

0.069

0.000*

No Charge

-0.151

0.189

1.000

Other

-0.667

0.097

0.000*

Medicaid

Private

Self Pay
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Payer (I)

Payer (J)

Mean Difference

Std. Error

Sig. (p)

No Charge

Medicare

-1.221

0.179

0.000*

Medicaid

-0.542

0.182

0.000*

Private

-0.603

0.181

0.000*

0.151

0.189

1.000

Other

-0.517

0.193

0.021*

Medicare

-0.705

0.075

0.000*

Medicaid

-0.025

0.081

1.000

Private

-0.087

0.079

0.990

Self Pay

0.667

0.097

0.000*

No charge

0.517

0.193

0.021*

Self

Other

Post-hoc Hochberg Analysis
Significant patient variable – Payer
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 20. Differences within significant patient variable (patient location) for length
of stay (LOS): NIS 2005 (N= 125,584)
Patient
location (I)

Patient
location (J)

Large metropolitan

Small metropolitan

Small metropolitan

Micropolitan

Mean Difference

Std. Error

Sig. (p)

0.187

0.025

0.000*

Micropolitan

0.413

0.031

0.000*

Non-urban

0.737

0.032

0.000*

-0.187

0.025

0.000*

Micropolitan

0.227

0.033

0.000*

Non-urban

0.551

0.034

0.000*

Large metropolitan

-0.413

0.031

0.000*

Small metropolitan

-0.227

0.033

0.000*

0.324

0.039

0.000*

Large metropolitan

-0.737

0.032

0.000*

Small metropolitan

-0.551

0.034

0.000*

Micropolitan

-0.324

0.039

0.000*

Large metropolitan

Non-urban
Non-urban

Post-hoc Hochberg Analysis
Significant patient variable – Patient location
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 21. Differences within significant patient variable (median income) for length of
stay (LOS): NIS 2005 (N= 125,584)
Income (I)

Income (J)

$1- $36,999

$37,000- $45,999

$37,000- $45,999

$46,000- $60,999

$1- $36,999

Mean Difference

Std. Error

Sig. (p)

-0.089

0.026

0.000*

$46,000- $60,999

-0.241

0.028

0.000*

$61,000 or more

-0.535

0.032

0.000*

0.089

0.026

0.000*

$46,000- $60,999

-0.151

0.029

0.000*

$61,000 or more

-0.446

0.033

0.000*

$1- $36,999

0.241

0.028

0.000*

$37,000- $45,999

0.151

0.029

0.000*

$61,000 or more

-0.294

0.034

0.000*

$1- $36,999

0.535

$37,000- $45,999

0.446

0.033

0.000*

$46,000- $60,999

0.294

0.034

0.000*

$1- $36,999

Post-hoc Hochberg Analysis
Significant patient variable – Patient location
*Significance is at the 0.05 level
Mean Difference = I – J
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0.032

0.000*

LOS by hospital-related variables
The results indicated that LOS was highest in hospitals in the Northeastern region
(5.42 days, S.D. = 3.98) and lowest in the Western region (4.36 days, S.D. = 3.61) (Refer
Table 19). With respect to hospital’s location and teaching status, LOS was high in urban
areas (4.85 days, S.D. = 3.76 in urban non-teaching and 4.80 days, S.D. = 3.84 in urban
teaching), as compared to the hospitals in rural areas (4.25 days, S.D. = 3.06). LOS was
lowest in hospitals with small bed-size (4.39 days, S.D. = 3.68).
A one-way ANOVA was conducted to detect differences in LOS across different
levels of hospital-related variables (Refer Table 23). All of the hospital-related variables
were found to be significant (p < 0.050). Post-hoc Hochberg analyses were further
conducted, to tease out the differences among the levels of the significant hospital
variables.
On comparing the different region categories of hospital, significant differences
were seen among almost all of the regions (Refer Table 24). The highest difference was
seen between the LOS in hospitals in the Western region and hospitals in the
Northeastern region, and the difference was lowest between the hospital in the Western
region and those in the Southern region. Patients from hospitals in the Western region
had smaller LOS as compared to patients from hospitals in the Northeastern region as
well as from those in the Southern region (1.06 days shorter, and 0.30 days respectively).
There were significant differences between patients from hospitals with small, medium,
and large bed-sizes (Refer Table 25). The difference was highest between those in
hospitals with larger bed-size and those patients in hospitals with smaller bed-size.
Patients from hospitals with larger bed-size had a longer LOS (0.44 days). In terms of
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LOS, significant differences were seen across all the three categories of hospital locationteaching status, the highest difference being between patients from hospitals in the urban
non-teaching setting and those from hospitals in rural setting (Refer Table 26). Patients
from hospitals in the urban settings had a relatively longer LOS than the patients from
hospitals in the rural setting (0.60 days longer in urban non-teaching and 0.55 days longer
in urban teaching setting).
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Table 22. Differences in length of stay (LOS) by hospital variables: NIS 2005
(N= 125,845)
Hospital variables

Level of
hospital variables

Mean LOS
(days)

S.D.

Geographic Region

Northeast

5.42

3.98

Midwest

4.38

3.28

South

4.66

3.62

West

4.36

3.61

Total

4.69

3.63

Rural

4.25

3.06

Urban non-teaching

4.85

3.76

Urban teaching

4.80

3.84

Total

4.69

3.63

Small

4.39

3.68

Medium

4.58

3.52

Large

4.83

3.67

Total

4.69

3.63

Location

Bed Size

LOS = Length of stay
S.D. = Standard deviation
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Table 23. Differences between hospital variables for length of stay (LOS):
NIS 2005 (N =125,845)
Hospital variables

Test statistics

Sig. (p)

Geographic Region

F = 426.15a

0.000*

Location

F = 311.69a

0.000*

Bed-Size

F = 138.10a

0.000*

a

One-way ANOVA
Independent t-test
Dependent variable: LOS
*Significance is at the 0.05 level
b
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Table 24. Differences within significant hospital variable (region) for length of stay
(LOS): NIS 2005 (N =125,845)
Region (I)

Region (J)

Northeast

Midwest

South

West

Mean Difference

Std. Error

Sig. (p)

Midwest

1.042

0.032

0.000*

South

0.764

0.028

0.000*

West

1.065

0.037

0.000*

Northeast

-1.042

0.032

0.000*

South

-0.278

0.026

0.000*

West

0.023

0.035

0.986

Northeast

-0.764

0.028

0.000*

Midwest

0.278

0.026

0.000*

West

0.301

0.032

0.000*

Northeast

-1.065

0.037

0.000*

Midwest

-0.023

0.035

0.986

South

-0.301

0.032

0.000*

Post-hoc Hochberg Analysis
Significant patient variable – Geographic location of hospital
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 25. Differences within significant hospital variable (hospital bed size) for length
of stay (LOS): NIS 2005 (N =125,584)
Hospital
bed size (I)

Hospital
bed size (J)

Small

Medium

Medium

Large

Mean Difference

Std. Error

Sig. (p)

-0.189

0.032

0.000*

Large

-0.436

0.028

0.000*

Small

0.189

0.032

0.000*

Large

-0.247

0.024

0.000*

Small

0.436

0.028

0.000*

Medium

0.247

0.024

0.000*

Post-hoc Hochberg Analysis
Significant patient variable – Hospital bedsize
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 26. Differences within significant hospital variable (location/teaching status)
for length of stay (LOS): NIS 2005 (N= 125,584)
Hospital
loc-teach (I)

Hospital
loc-teach (J)

Mean
Difference

Std. Error

Sig. (p)

Rural

Urban non-teaching

-0.603

0.025

0.000*

Urban teaching

-0.550

0.029

0.000*

Urban

Rural

0.603

0.025

0.000*

non-teaching

Urban teaching

0.053

0.025

0.019*

Urban

Rural

0.550

0.029

0.000*

teaching

Urban non-teaching

-0.053

0.025

0.019*

Post-hoc Hochberg Analysis
Significant patient variable – Hospital bedsize
*Significance is at the 0.05 level
Mean Difference = I – J
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Objective 4: Differences in total hospital costs by patient‐related and hospital‐related
variables
The overall differences in total hospital costs by patient and hospital variables
were observed for the year 2005. This analysis involved comparing mean total hospital
costs within categories of different patient- and hospital-related variables. The mean total
hospital costs were found to be approximately $7,383.66 (S.D. = 8,819.07) per
hospitalization related to COPD.

Total hospital costs by patient‐related variables
The results indicated that mean costs per hospitalization increased with age, and
the hospital costs were highest on an average, for patients in the age group 81+ years
($7,162.73, S.D. = 7,094.52). It was observed that Hispanics had the highest per
hospitalization ($8,600.73, S.D. =9,976.90), followed by African Americans ($7,872.68 ,
S.D. = 8,819). Caucasians had the least costs per hospitalization ($7,173.65 S.D. =
8,070.61). Females ($6,986.66, S.D. =7,651.29) had slightly higher mean costs per
hospitalization as compared to males ($6,880, S.D. = 7,893.91). Mean costs per
hospitalization were found to be the lowest for patients who had no insurance ($4,953.75,
S.D. = 5,067.98). The mean costs per hospitalization were higher for patients with
Medicare and for patients with private insurance ($7,130.74, S.D = 7,772.85 for Medicare
and $6,710.62, S.D = 8,618.62 for private insurance). Also, patients who were located in
non-urban areas had the lowest mean costs compared to patients living in other locations.
Mean costs per hospitalization were also found to increase, with increasing income levels
of the patients.
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A one-way ANOVA was conducted for all the patient variables, except gender.
All patient level variables were found to be significant (p < 0.050) (Refer Table 28).
Post-hoc Hochberg analyses were then conducted, to further tease out the differences
among the levels of the significant patient variables.
The different categories of age were compared, and significant differences were
seen among all the categories of age. Refer Table 29. However, the difference between
the groups 81+ years and 0-20 years was highest (the mean costs were $2,245 higher for
patients, 81+ years of age). In terms of mean costs, significant differences were seen
amongst patients of all races (Refer Table 30). Caucasians had lower mean costs per
hospitalization as compared to both Hispanics ($1,427 less), as well as African
Americans ($699 less). There were significant (p < 0.001) differences between patients
with different Payers, in almost all categories of Payers (Refer Table 31). The difference
was highest between those with Medicare and those patients with no insurance. Patients
under Medicare were observed to have higher mean costs per hospitalization ($2,176
more than patients with no insurance). Least difference was seen between mean costs of
patients with Medicare and patients with private insurance (mean costs only $420 higher
for patients with Medicare). Significant differences (p < 0.001) were also seen among all
the categories of patient location, the difference being largest between the patient living
in the large metropolitan areas and those living in the non-urban areas (Refer Table 32).
The patients in the large metropolitan areas had relatively higher mean costs per
hospitalization ($10,486.94). Among the patient median income groups, significant
differences (p < 0.001) in mean costs were seen across all the levels. The least difference
in mean costs was seen in patients in the income group $37,000 - $45,999 and those in
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the income group $1- $36,999, with the patients in the $37,000 - $45,999 group having
higher mean costs ($473 more).
A difference in total mean costs between males and females was tested using
Independent t-test; and the differences between males and females were not found to be
statistically significant (p < 0.05).
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Table 27. Differences in total hospital costs by patient variables: NIS 2005
(N= 125,584)
Patient variables

Level of

Mean total

patient variables

costs ($) per

S.D.

hospitalization
Age (years)

0-20

4,917.09

9,775.36

(68.83 ± 13.31)*

21-40

5,378.72

6,424.86

41-64

6,617.11

8,141.72

65-80

7,142.21

7,743.18

81+

7,162.73

7,094.52

Total

6,939.61

7,758.61

Caucasian

7,173.65

8,070.61

African American

7,872.68

8,819.07

Hispanic

8,600.73

9,976.90

Others

8,767.56

10,601.16

Total

7,309.23

8,273.49

Male

6,880.97

7,893.91

Female

6,986.66

7,651.29

Medicare

7,130.74

7,772.85

Medicaid

6,484.98

7,162.72

Private

6,710.62

8,618.62

Self Pay

5,325.03

5,416.04

No charge

4,953.75

5,067.98

Others

6,039.56

5,685.31

Total

6,940.47

7,759.67

Race

Gender

Payer
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Patient variables

Level of

Mean total

patient variables

costs ($) per

S.D.

hospitalization
Patient Location

Income

Large Metropolitan

8,035.24

8,983.93

Small Metropolitan

6,442.47

7,212.26

Micropolitan

5,950.47

5,824.48

Non-urban

5,590.29

5,356.69

Total

6,936.58

7,707.89

$1- $36,999

6,121.03

6,687.12

$37,000 – $45,999

6,594.85

7,121.59

$46,000 – $60,999

7,447.29

8,229.27

$61,000 +

8,649.13

9,597.80

Total

6,951.39

7,733.41

* Mean ± S.D.
S.D. = Standard deviation
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Table 28. Differences between patient variables for total hospital costs: NIS 2005 (N=
125,584)
Patient variables

Test Statistics

Sig. (p)

Age

F = 57.10a

0.000*

Race

F = 55.00a

0.000*

Payer

F = 54.24a

0.000*

Patient Location

F = 633.88a

0.000*

Income

F = 483.82a

0.000*

Gender

T-test = -1.468b

1.43

a

One-way ANOVA
Independent t-test.
Dependent variable: Total hospital charges
*Significance is at 0.05 level

b
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Table 29. Differences within significant patient variable (age) for total hospital costs:
NIS 2005 (N =125,584)
Age (I)

Age (J)

0-20 years

21-40 years

21-40 years

41-64 years

65-80 years

81+ years

Mean Difference

Std. Error

Sig. (p)

-461.63

365.84

0.895

41-64 years

-1,700.02

316.95

0.000*

65-80 years

-2,225.12

316.12

0.000*

81+ years

-2,245.64

318.76

0.000*

0-20 years

461.63

365.84

0.895

41-64 years

-1,238.38

191.52

0.000*

65-80 years

-1,763.48

190.13

0.000*

81+ years

-1,784.01

194.50

0.000*

0-20 years

1,700.02

316.95

0.000*

21-40 years

1,238.38

191.52

0.000*

65-80 years

-525.09

52.62

0.000*

81+ years

-545.62

62.61

0.000*

0-20 years

2,225.12

316.12

0.000*

21-40 years

1,763.48

190.13

0.000*

41-64 years

525.09

52.62

0.000*

81+ years

-20.52

62.61

1.000

0-20 years

2,245.64

318.76

0.000*

21-40 years

1,784.01

194.50

0.000*

41-64 years

545.62

66.70

0.000*

65-80 years

20.52

62.61

1.000

Post-hoc Hochberg Analysis
Significant patient variable – Age
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 30. Differences within significant patient variable (race) for total hospital costs:
NIS 2005 (N =125,584)
Race (I)

Race (J)

Caucasian

African American

African American

Hispanic

Mean Difference

Std. Error

Sig. (p)

-699.03

116.83

0.010*

Hispanic

-1,427.07

160.61

0.010*

Others

-1,593.90

200.22

0.010*

Caucasian

699.03

116.83

0.010*

Hispanic

-728.04

193.45

0.011*

Others

-894.87

227.41

0.011*

Caucasian

1,427.07

160.61

0.010*

African American

728.04

193.45

0.011*

-166.83

252.71

0.986

Others
Others

Caucasian

1,593.90

200.22

0.010*

African American

894.87

227.41

0.011*

Hispanic

166.83

252.71

0.986

Post-hoc Hochberg Analysis
Significant patient variable – Race
*Significance is at the 0.05 level
Mean Difference = I – J

91

Table 31. Differences within significant patient variable (payer) for total hospital
costs: NIS 2005 (N= 125,584)

Payer (I)

Payer (J)

Medicare

Medicaid

Medicaid

Private

Self Pay

Mean Difference

Std. Error

Sig. (p)

645.76

79.27

0.000*

Private

420.12

67.52

0.000*

Self Pay

1,805.71

150.38

0.000*

No charge

2,176.99

426.87

0.000*

Other

1,091.18

67.70

0.000*

Medicare

-645.76

79.27

0.000*

Private

-225.63

96.84

0.207

Self Pay

1,159.94

165.64

0.000*

No Charge

1,531.23

432.47

0.000*

Other

445.42

181.50

0.135

Medicare

-420.12

67.52

0.000*

Medicaid

225.63

96.84

0.207

Self Pay

1,385.58

160.34

0.000*

No Charge

1,756.87

430.47

0.000*

Other

671.05

176.68

0.000*

Medicare

-1,805.71

150.38

0.000*

Medicaid

-1,159.94

165.64

0.000*

Private

-1,385.58

160.34

0.000*

371.28

450.96

1.000

-714.52

221.98

0.000*

No Charge
Other
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Payer (I)

Payer (J)

Mean Difference

No Charge

Medicare

Other

Std. Error

Sig. (p)

-2,176.99

426.87

0.000*

Medicaid

-1,531.23

432.47

0.000*

Private

-1,756.87

430.47

0.000*

Self

-371.28

450.96

1.000

Other

-1,085.81

457.03

0.179

Medicare

-1,091.18

67.70

0.000*

Medicaid

-445.42

181.50

0.135

Private

-671.05

176.68

0.000*

Self Pay

714.52

221.98

0.000*

No charge

1,085.81

457.03

0.179

Post-hoc Hochberg Analysis
Significant patient variable – Payer
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 32. Differences within significant patient variable (patient location) for total
hospital costs: NIS 2005 (N= 125,584)
Patient
location (I)

Patient
location (J)

Large metropolitan

Small metropolitan

1,592.77

54.87

0.000*

Micropolitan

2,084.77

67.31

0.000*

Non-urban

2,444.95

71.19

0.000*

Large metropolitan

-1,592.77

54.87

0.000*

Micropolitan

492.00

71.73

0.000*

Non-urban

852.18

75.37

0.000*

Large metropolitan

-2,084.77

67.31

0.000*

Small metropolitan

-492.00

71.73

0.000*

360.18

84.86

0.000*

Large metropolitan

-2,444.95

71.19

0.000*

Small metropolitan

-852.18

75.37

0.000*

Micropolitan

-360.18

84.86

0.000*

Small metropolitan

Micropolitan

Mean Difference

Non-urban
Non-urban

Post-hoc Hochberg Analysis
Significant patient variable – Patient location
*Significance is at the 0.05 level
Mean Difference = I – J
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Std. Error

Sig. (p)

Table 33. Differences within significant patient variable (median income) for total
hospital costs: NIS 2005 (N= 125,584)
Income (I)

Income (J)

$1- $36,999

$37,000- $45,999

$37,000- $45,999

$46,000- $60,999

$61,000+

Mean Difference

Std. Error

Sig. (p)

-473.81

58.74

0.000*

$46,000- $60,999

-1,326.25

62.98

0.000*

$61,000+

-2,528.09

70.71

0.000*

$1- $36,999

473.81

58.74

0.000*

$46,000- $60,999

-852.43

64.84

0.000*

$61,000+

-2,054.28

72.37

0.000*

$1- $36,999

1,326.25

62.98

0.000*

$37,000- $45,999

852.43

64.84

0.000*

$61,000+

-1,201.84

75.86

0.000*

$1- $36,999

2,528.09*

70.71

0.000*

$37,000- $45,999

2,054.28*

72.37

0.000*

$46,000- $60,999

1,201.84*

75.86

0.000*

Post-hoc Hochberg Analysis
Significant patient variable – Patient location
*Significance is at the 0.05 level
Mean Difference = I – J
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Total hospital costs by hospital-related variables
The mean costs per hospitalization were found to be the highest for hospitals
located in the Western region ($9,378.43, S.D. = 12,461.73) and lowest for those located
in the Southern region ($5,747.31, S.D. = 5,516.07). Hospitals with teaching status in
urban areas had higher mean costs per hospitalization ($7,908.41, S.D. =10,355)
compared to rural hospitals ($5,645.29, S.D. = 5,072.56). Hospitals with large bed sizes
had the highest mean costs per hospitalization ($7,272.00, S.D. =8,337.15) than hospitals
with small or medium bed sizes (Refer Table 34).
One-way ANOVA were then conducted for all hospital-related variables, which
indicated that the differences for geographic region, hospital bed size and location
/teaching status were all statistically significant (Refer Table 35). A post-hoc Hochberg
test was conducted to see the differences among these variables.
On comparing the different region categories of hospital, significant differences
were seen among almost all four regions (Refer Table 36). The highest difference was
seen between the mean costs in hospitals in the Western region and hospitals in the
Southern region, and the difference was lowest between the hospitals in the Midwestern
region and those in the Southern region. The post-hoc tests also showed significance
difference between hospitals located in urban areas with teaching facilities compared to
hospitals located in rural areas (p<0.001). The results showed that teaching hospitals in
urban areas had higher mean costs per hospitalization ($2,263.11) than hospitals in rural
areas (Refer Table 37). There were also significant (p < 0.001) differences in costs for
patients from hospitals with small, medium, and large bed-sizes (Refer Table 38). The
difference was highest between those in hospitals with larger bed-size and those patients
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in hospitals with smaller bed-size. Patients from hospitals with larger bed-size had higher
mean costs ($1,088.37 more).
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Table 34. Differences in total hospital costs by hospital variables: NIS 2005
(N= 125,845)
Hospital variables

Level of

Mean total

hospital variables

costs ($) per

S.D

hospitalization
Geographic Region

Location

Bed-size

Northeast

8,649.14

8,690.17

Midwest

6,270.35

6,201.74

South

5,747.31

5,516.07

West

9,378.43

12,461.73

Total

6,939.94

7,759.51

Rural

5,645.29

5,072.56

Urban non-teaching

7,152.18

7,394.35

Urban teaching

7,908.41

10,355.40

Total

6,939.94

7,759.51

Small

6,183.63

6,560.40

Medium

6,716.97

7,126.57

Large

7,272.00

8,337.15

Total

6,939.94

7,759.51

S.D. = Standard deviation
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Table 35. Differences between significant hospital variables for total hospital costs:
NIS 2005 (N= 125,845)
Hospital variables

Test Statistics

Sig. (p)

Geographic Region

F = 1355.46a

0.000*

Location / Teaching status

F = 647.23a

0.000*

Bed-size

F = 163.22a

0.000*

a

One-way ANOVA
Dependent variable: Total hospital charges
*Significance is at the 0.05 level
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Table 36. Differences within significant hospital variable (region) for total hospital
costs: NIS 2005 (N= 125,845)
Region (I)

Region (J)

Northeast

Midwest

2,378.79

67.76

0.000*

South

2,901.83

61.89

0.000*

West

-729.28

79.96

0.000*

Northeast

-2,378.79

67.76

0.000*

South

523.04

56.85

0.000*

West

-3,108.07

76.12

0.000*

Northeast

-2,901.83

61.89

0.000*

Midwest

-523.04

56.85

0.000*

West

-3,631.11

70.96

0.000*

Northeast

729.28

79.96

0.000*

Midwest

3,108.07

76.12

0.000*

South

3,631.11

70.95

0.000*

Midwest

South

West

Mean Difference

Post-hoc Hochberg Analysis
Significant patient variable – Geographic location of hospital
*Significance is at the 0.05 level
Mean Difference = I – J
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Std. Error

Sig. (p)

Table 37. Differences within significant hospital variable (hospital location‐teaching)
for total hospital costs: NIS 2005 (N= 125,845)
Hospital
loc-teach (I)

Hospital
loc-teach (J)

Mean
Difference

Std. Error

Sig. (p)

Rural

Urban non-teaching

-1,506.88

55.25

0.000*

Urban teaching

-2,263.11

65.16

0.000*

Urban

Rural

1,506.88

55.25

0.000*

non-teaching

Urban teaching

-756.23

57.08

0.000*

Urban

Rural

2,263.11

65.16

0.000*

teaching

Urban non-teaching

756.23

57.08

0.000*

Post-hoc Hochberg Analysis
Significant patient variable – Hospital bed size
*Significance is at the 0.05 level
Mean Difference = I – J
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Table 38. Differences within significant hospital variable (hospital bed‐size) for total
hospital costs: NIS 2005 (N= 125,845)
Hospital
bed size (I)

Hospital
bed size (J)

Small

Medium

Medium

Large

Mean Difference

Std. Error

Sig. (p)

-533.33

71.38

0.000*

Large

-1,088.37

63.67

0.000*

Small

533.33

71.38

0.000*

Large

-555.03

53.95

0.000*

Small

1088.37

63.67

0.000*

Medium

555.03

53.95

0.000*

Post-hoc Hochberg Analysis
Significant patient variable – Hospital bedsize
*Significance is at the 0.05 level
Mean Difference = I – J
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Objective 5: Differences in in‐hospital mortality by patient‐related and hospital‐
related variables
The overall differences in in-hospital mortality by patient and hospital variables
were observed for the year 2005 using Cross tabulations. A total of 2,451 (2.0%) inhospital deaths were observed in the sample for the year 2005, with COPD as a primary
diagnosis on record.

In‐hospital deaths by patient‐related variables
The proportion of in-hospital deaths as a hospitalization outcome increased with
increasing age, and was higher for males (2.2%) as compared to females (1.8%). Results
indicated that proportion of in-hospital deaths was highest (3.2%) for patients in the age
group 81+ years, and lowest (0.1%) for patients in the age group 21-40 years. Caucasians
(2.2%) were seen to have a higher proportion of in-hospital deaths as compared to
African Americans (1.3%) and Hispanics (1.7%). Higher proportion of in-hospital
mortality was observed in patients with Medicare (2.1%) and those with private insurance
(2%). Patients who were located in non-urban areas reported lower (1.7%) proportions of
in-hospital mortality, as compared to patients living in other locations (Table 39).

In‐hospital deaths by hospital‐related variables
The proportion of in-hospital deaths was observed to be relatively higher (2.6%)
in the hospitals from Northeastern part of the US. More in-hospital deaths were reported
in the hospitals in the urban setting, and also in hospitals with large bed-sizes (Table 40).
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Table 39. Differences in in‐hospital mortality by patient variables: NIS 2005 (N =125,845)
Patient variables

Level of

Did not die

Died

Total

patient variables
Age (years)
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Race

Gender

0-20

794 (99.7)

2 (0.3)

796

21-40

1,849 (99.9)

2 (0.1)

1,851

41-64

39,559 (99.2)

327 (0.8)

39,886

65-80

57,754 (97.7)

1,359 (2.3)

59,113

81+

23,112 (96.8)

761 (3.2)

23,873

Total

123,068 (98.0)

2451 (2.0)

125,519

74,448 (97.8)

1,642 (2.2)

76,090

African American

6,487 (98.7)

85 (1.3)

6,572

Hispanic

4,086 (98.3)

69 (1.7)

4,155

Others

2,169 (98.1)

42 (1.9)

2,211

Total

87,190 (97.9)

1,838 (2.1)

89,028

Male

54,143 (97.8)

1,217 (2.2)

55,360

Female

68,886 (98.2)

1,234 (1.8)

70,120

Total

123,029 (98.0)

2,451 (2.0)

125,480

Caucasian

Patient variables

Level of variable

Did not die

Died

Total

Payer

Medicare

88,282 (97.9)

1,934 (2.1)

90,216

Medicaid

11,570 (99.3)

82 (0.7)

11,652

Private

17,140 (98.0)

352 (2.0)

17,492

Self Pay

3,277 (99.3)

23 (0.7)

3,300

407 (99.3)

3 (0.7)

410

2,330 (97.7)

55 (2.3)

2,385

123,006 (98.0)

2,449 (2.0)

125,455

Large Metropolitan

53,988 (98.0)

1,097 (2.0)

55,085

Small Metropolitan

34,136 (97.9)

719 (2.1)

34,855

Micropolitan

18,545 (98.1)

354 (1.9)

18,899

Non-urban

16,161 (98.3)

279 (1.7)

16,440

122,830 (98.0)

2,449 (2.0)

125,279

$1- $36,999

40,793 (98.3)

699 (1.7)

41,492

$37,000 – $45,999

34,033 (98.1)

667 (1.9)

34,700

$46,000 – $60,999

26,555 (97.8)

597 (2.2)

27,152

$61,000 +

18,663 (97.7)

446 (2.3)

19,109

120,044 (98.0)

2,409 (2.0)

122,453

No charge
Others
Total
Patient Location
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Total
Income

Total

Table 40. Differences in in‐hospital mortality by hospital variables: NIS 2005 (N= 125,845)
Patient variables

Level of

Did not die

Died

Total

patient variables
Geographic Region
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Location

Bed-size

Northeast

21,805 (97.4)

590 (2.6)

22,395

Midwest

28,617 (98.1)

553 (1.9)

29,170

South

56,738 (98.3)

958 (1.7)

57,696

West

15,932 (97.9)

350 (2.1)

16,282

Total

123,092 (98.0)

2,451 (2.0)

125,543

Rural

31,096 (98.2)

557 (1.8)

31,653

Urban non-teaching

62,688 (98.0)

1,262 (2.0)

63,950

Urban teaching

29,308 (97.9)

632 (2.1)

29,940

Total

123,092 (98.0)

2,451 (2.0)

125,543

Small

20,830 (98.1)

404 (1.9)

21,234

Medium

33,294 (98.2)

599 (1.8)

33,893

Large

68,968 (97.9)

1,448 (2.1)

70,416

Total

123,092 (98.0)

2,451 (2.0)

125,543

Objective 6: Patient‐ and hospital‐related predictors of hospital LOS .
To assess the predictors of LOS, multiple regression analyses were conducted,
and dummy variables were used for variables with more than two levels.

Predictors of length of stay (LOS)
A multiple linear regression was conducted to find the variables that predicted
LOS in hospitalized patients with COPD. An ‘Enter’ regression was conducted to
determine significant predictors and further a ‘Stepwise’ regression was conducted to
find out the predictors, which contributed most to the variance in LOS (Refer Tables 41,
42).

The regression analysis conducted by the Enter method found most variables to be
significant predictors for LOS (i.e. had a p-value of ≤ 0.05). The variables not found to be
significant were the race African American, the ‘other’ category of health insurance, the
micropolitan patient location, the $61,000+ income group, and the urban-teaching
hospital setting.
Males had a smaller (0.3 days less) LOS as compared to females. Both patients
with no health insurance (0.5 days less), patients with private insurance had a smaller
LOS (0.5 days, and 0.2 days less) as compared to those with Medicare in the regression
model. Also patients from the Western and Midwestern region had LOS smaller than
those from the Southern region (0.7days less and 0.5 days less respectively). Patients
from small bed size hospitals had 0.3 days smaller LOS than from large bed size
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hospitals. Patients who had Elective type of hospital admission had a shorter LOS stay
(0.5 days less) in the regression model.
The results for Stepwise method of multiple linear regression analysis for hospital
LOS of COPD patients are shown in Table 41. Only significant variables (p< 0.001)
entered the model, and the final model (Step 3) accounted for 19.3% of the variance in
hospital LOS, where Number of procedures accounted for most of the variance (13.5%).
The other significant predictors (sequentially in the order of inclusion in the model) that
entered in this model were Number of diagnoses, Midwestern region, Western region,
Gender (female), Elective type of hospital admission, Urban non-teaching hospital
setting, patients with no insurance or private insurance, patients with Medicaid, North
eastern region, small and medium bed size hospital setting, and small metropolitan area.
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Table 41. Factors associated with length of stay (LOS) for COPD – related
hospitalizations: NIS 2005(N= 125,845) {Enter Method}
Model
Variables
Age
Race

Gender

B

SE

Location

Income

Sig.

0.015

0.001

18.01

0.000*

African American

0.020

0.042

0.462

0.644

Hispanic

0.149

0.052

2.844

0.004*

Others

0.369

0.070

5.252

0.000*

-0.328

0.19

-0.045

0.000*

Levels
Caucasian†

Female†
Male

Payer

t

Medicare†
Medicaid

-0.151

0.036

-4.148

0.000*

Pvt. Insurance

-0.209

0.030

-7.069

0.000*

Self-pay

-0.564

0.060

-9.390

0.000*

Other

-0.126

0.069

-1.841

0.066

Small Metro

-0.149

0.023

-6.353

0.000*

Micropolitan

-0.085

0.047

-1.796

0.073

Non-Core

-0.174

0.048

-3.623

0.000*

$37,000 – $45,999

-0.075

0.025

-0.009

0.002*

$45,000 – $60,999

-0.077

0.028

-0.009

0.006*

$61,000 +

0.002

0.033

0.065

Large Metro†

$1,000 - $36,999†
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0.948

Model
Variables
Geog. Region

B

SE

t

Sig.

Northeast

0.192

0.028

6.984

0.000*

Midwest

-0.490

0.024

-20.220

0.000*

West

-0.743

0.030

-24.972

0.000*

Levels
South†

Location/

Rural†

Teaching

Urban non-teaching

0.220

0.044

5.012

0.000*

Urban teaching

-0.041

0.046

-0.895

0.371

Bed-size

Large†
Small

-0.293

0.026

-11.132

0.000*

Medium

-0.222

0.022

-10.140

0.000*

-18.120

0.000*

71.149

0.000*

124.649

0.000*

Admission

Non-elective†

Type

Elective

-0.548

-

0.220

-

1.041

Number of

0.030
0.003

diagnoses
Number of

0.008

procedures
Multiple Linear Regression Analysis – Enter Method, all variables entered.
Dependent variable: LOS
*Significance is at 0.05 level
†
Reference category
B = Regression Coefficient; SE = Standard Error of the regression coefficients; t = t-test (ratio of the
sample regression coefficient B to its standard error)
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Table 42. Factors associated with length of stay (LOS) for COPD – related
hospitalizations: NIS 2005 (N= 125,845) {Stepwise Method}
B

SE

β

Constant

4.159

0.010

Number of procedures

1.168

0.008

Constant

2.494

0.024

Number of procedures

1.031

0.008

0.325

Number of diagnoses

0.237

0.003

0.205

Constant

3.517

0.041

Number of procedures

1.035

0.008

0.326

Number of diagnoses

0.226

0.003

0.195

Midwest region

-0.499

0.024

-0.058

West region

-0.715

0.029

-0.066

Gender (Female)

-0.333

0.019

-0.046

Elective admission

-0.534

0.030

-0.046

Urban non-teaching setting

0.272

0.020

0.037

Payer- Self pay

-0.836

0.058

-0.037

Payer- Private and HMO

-0.420

0.027

-0.040

Payer-Medicaid

-0.442

0.032

-0.035

Northeast region

0.231

0.027

0.024

Small bed-size

-0.289

0.026

-0.030

Medium bed-size

-0.221

0.022

-0.027

Small metropolitan areas

-0.163

0.022

-0.020

R2

Step 1
0.135
0.367

Step 2
0.178

Step 3
0.193

Multiple Linear Regression Analysis – Stepwise Method, only significant variables entered.
Dependent variable: LOS
Significance is at 0.05 level
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B = Regression Coefficient; SE = Standard Error of the regression coefficients; β = Standardised regression
coefficient; R2 = Adjusted R2
Reference category = Race (Caucasians). Gender (Female), Payer (Medicare), Location (Large metro),
Income ($1-$35,999), Geographic region (South), Location/Teaching Status (Urban Teaching), Bed-size
(Large)
ΔR2 Step 1= 0.135
ΔR2 Step 2= 0.043
ΔR2 Step 3= 0.015
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Objective 7: Patient‐ and hospital‐related predictors of total hospital costs.
To assess the predictors of total hospital costs, multiple regression analyses were
conducted, and dummy variables were used for variables with more than two levels.

Predictors of total hospital costs
A multiple linear regression was conducted to test the variables that predict total
hospital charges. Just like for LOS, an ‘Enter’ regression to determine significant
predictors and further a ‘Stepwise’ regression was conducted to find out the predictors,
which contributed most to the variance in total hospital charges. Refer tables 43, 44.

By using Enter method in multiple linear regression analysis, it was found that
most patient-related and all hospital- related variables were significant predictors for total
hospital costs (i.e. had a p-value of ≤ 0.05). The variables not found to be significant were
no health insurance and patient income groups $37,000 - $45,999, and age at admission

Hispanics had a total of $910 higher charges per hospitalization than Caucasians
(reference group in dummy variables). Males had $170.89 lesser costs per hospitalization
than females (reference group in dummy variables). Those with no insurance had $617.57
lesser costs per hospitalization than those with Medicare (reference group in dummy
variables), also patients who lived in the non-urban areas had costs per hospitalization
$623.68 than those who lived in the large metropolitan areas (reference group in dummy
variables). Hospitals in the Western region had a total of $2,426 higher charges per
hospitalization than hospitals in the Southern region (reference group in dummy
variables), and hospitals in the urban non-teaching setting had $455.06 higher charges
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than hospitals in rural setting. Patients who had elective type of hospital admission had
$394.74 lesser charges per hospitalization than those who had a non-elective type of
hospital admission (reference group in dummy variables).

Table 43 shows the Stepwise method of multiple linear regression analysis for
total hospital costs of patients with COPD. Only significant variables (p< 0.001) entered
the model, and the final model (Step 3) accounted for 29.8% of the variance in total
hospital costs, with Number of procedures and Number of diagnosis again accounting for
most of the variance (27.2%). The other significant predictors (sequentially in the order
of inclusion in the model) that entered in this model were Western region, Northeastern
region, patients in the income group $61,000+, Micropolitan areas of patient location,
small and medium hospital bed size, the Hispanic race/ethnicity category, African
American race/ethnicity category, Elective type of hospital admission, and urban hospital
setting.
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Table 43. Factors associated with total hospital costs for COPD – related
hospitalizations: NIS 2005(N= 125,845) {Enter Method}
Model
Variables
Age
Race

Gender

Location

Income

SE

t

Sig.

-1.455

1.805

-0.806

0.420

Levels
Caucasian†
African American

691.915

93.078

7.434

0.000*

Hispanic

910.106

101.658

-1.885

0.059

Others

934.764

112.981

-1.114

0.034*

170.890

39.023

4.379

0.000*

Medicaid

-246.709

75.745

-3.257

0.001*

Pvt. Insurance

-188.896

62.556

-3.020

0.003*

Self-pay

-602.529

131.655

-4.577

0.000*

No charge

-617.577

360.965

-1.711

0.087

Other

-269.582

143.007

-1.885

0.059

Female†
Male

Payer

B

Medicare†

Large Metro†
Small Metro

-1,151.927

49.247

-23.391

0.000*

Micropolitan

-1,147.991

99.398

-11.549

0.000*

Non-Core

-623.686

101.726

-6.131

0.000*

$1,000 - $36,999†
$37,000 – $45,999

85.006

51.670

1.645

0.080

$46,000 – $60,999

361.578

58.543

6.176

0.000*

$61,000 +

950.646

69.266

13.724

0.000*
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Model

B

SE

t

Northeast

971.118

57.433

16.935

0.001*

Midwest

-237.744

50.360

-4.721

0.000*

West

2426.448

63.035

38.494

0.000*

Variables

Levels

Geog. Region

South†

Sig.

Location/

Rural†

Teaching

Urban teaching

-276.762

97.307

-2.844

0.004*

Urban non-teaching

-455.067

92.592

-4.915

0.000*

Small

-643.122

55.191

-11.653

0.000*

Medium

-523.436

46.145

-11.343

0.000*

-394.740

65.222

6.052

0.000*

-

432.029

6.585

65.606

0.000*

-

2,974.112

17.403

170.895

0.000*

Bed-size

Large†

Admission

Elective

Type

Non-elective

Number of
diagnoses
Number of
procedures

Multiple Linear Regression Analysis – Enter Method, all variables entered.
Dependent variable: Total hospital costs
*Significance is at 0.05 level
†
Reference category
B = Regression Coefficient; SE = Standard Error of the regression coefficients; t = t-test (ratio of the
sample regression coefficient B to its standard error)
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Table 44. Factors associated with total hospital costs for COPD – related
hospitalizations: NIS 2005 (N= 125,845) {Stepwise Method}
B

SE

β

R2

Step 1
Constant

5,429.07

21.62

Number of procedures

3,295.91

17.40

Constant

2,238.64

50.11

Number of procedures

3,040.04

17.42

0.452

Number of diagnoses

454.61

6.437

0.182

Constant

2,3298.42

77.43

Number of procedures

2968.30

17.32

0.400

Number of diagnoses

437.22

6.45

0.146

West region

2434.68

62.84

0.116

Northeast region

984.76

56.88

-0.067

Small metropolitan areas

-1137.81

49.16

$61,000 +

914.66

62.38

0.029

Micropolitan

-928.43

68.16

-0.070

Small bed-size

-633.80

49.29

-0.064

Race- Hispanic

876.26

98.56

0.044

Medium bed-size

-530.24

24.40

-0.037

Race- African American

653.91

41.35

0.030

$46,000- $60,999

318.21

40.94

0.022

Non-elective admission

-411.06

71.44

-0.021

Male sex

174.12

24.29

0.067

Non core areas

-426.60

61.60

0.045

Midwest region

-229.00

18.01

-0.013

Urban non teaching setting

-212.36

-14.03

-4.573

0.240
0.490

Step 2
0.272

Step 3
0.298

Multiple Linear Regression Analysis – Stepwise Method, only significant variables entered.
Dependent variable: Total hospital costs
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Significance is at 0.05 level
B = Regression Coefficient; SE = Standard Error of the regression coefficients; β = Standardised regression
coefficient; R2 = Adjusted R2
Reference category = Race (Caucasians). Gender (Female), Payer (Medicare), Location (Large metro),
Income ($1-$35,999), Geographic region (South), Location/Teaching Status (Urban Teaching), Bed-size
(Large)
ΔR2 Step 1= 0.240
ΔR2 Step 2= 0.272
ΔR2 Step 3= 0.298
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Objective 8: Patient‐ and hospital‐related predictors of in‐hospital mortality.
To assess the predictors of in-hospital mortality, binary logistic regression
analyses were conducted, and dummy variables were used for variables with more than
two levels.

Predictors of length of in-hospital mortality
The Forward Wald method was used, and only significant predictors entered the
model, and the final model (Step 3) accounted for 22% of the variance in in-hospital
mortality, with Number of procedures alone accounting for most of the variance (14%).
The other significant predictors (sequentially in the order of inclusion in the model) that
entered in this model were Age, Number of diagnoses, Private payer, non-elective type
of hospital admission, gender, the race African American, and Medium bed-size hospital
setting.
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Table 45. Factors associated with in‐hospital mortality for COPD – related
hospitalizations: NIS 2005 (N= 125,845) {Forward Wald Method}
B

SE

Wald

Constant

-4.301

0.025

30340.15

Number of procedures

0.423

0.009

2307.32

Constant

-8.527

0.177

2311.37

Number of procedures

0.403

0.010

1750.80

Age

0.054

0.002

651.85

Number of diagnoses

0.068

0.006

124.93

Payer- Private and HMO

0.631

0.064

96.70

Non elective admission

-0.423

0.061

47.90

Payer-Other

0.745

0.143

27.14

Gender (Male)

0.229

0.042

29.49

Race- African American

-0.286

0.114

6.277

Medium bed-size

-0.121

0.049

6.090

R2

Step 1

0.014

Step 2

0.022

Logistic Regression Analysis – Forward Wald Method, only significant variables entered.
Dependent variable: In-hospital mortality
Significance is at 0.05 level
B = Regression Coefficient; SE = Standard Error of the regression coefficients; β = Standardised regression
coefficient; R2 = Adjusted R2
Reference category = Race (Caucasians). Gender (Female), Payer (Medicare), Location (Large metro),
Income ($1-$35,999), Geographic region (South), Location/Teaching Status (Urban Teaching), Bed-size
(Large)
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Objective 9: Trends in hospital LOS, total hospital charges, and in‐hospital deaths for
years 2002‐2005
Descriptive analysis was conducted using NIS datasets for the years 2002-2005 to
determine trends in hospital LOS, total hospital charges and number of in-hospital deaths.
The number of hospitalized cases with COPD listed as the primary diagnosis was
126,504 cases, 127,393 cases, 112,983 cases, and 126,130 cases in the year 2005 in the
year 2002, 2003, 2004 and 2005 respectively.
The results also showed a decreasing trend in the hospital LOS, it being highest
for the year 2002 (4.88 days, S.D = 3.76). Refer Table 46, and highest for the year 2005
(4.69 days, S.D = 3.63). The charges however showed an increasing trend. The total
hospital charges per hospitalization were highest for the year 2005 . In terms of inhospital mortality, there was a decreasing trend, which appeared to level off towards the
end.
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Table 46. Trends in hospital length of stay (LOS) and total hospital costs (THC): NIS,
2002‐2005
Variables

Years
2002

2003

2004

2005

N

126,504

127,393

112,983

126,130

Mean LOS (days)

4.88

4.76

4.71

4.69

Mean THC ($)*

6,958

7,206

7,293

7,383

Deaths

3,355

3,052

2,570

2,587

N = Number of hospitalizations in each year
THC= Total hospital costs
* Inflated costs (2005 values)
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Figure 2: Trends in hospital LOS, NIS 2002‐2005.

123

Figure 3: Trends in mean total hospital costs (Inflated, 2005 values),
2005.
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NIS 2002‐

Figure 4: Trends in in‐hospital mortality, NIS 2002‐2005.
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CHAPTER FIVE
DISCUSSION AND CONCLUSIONS

In this chapter, implications and study limitations will be presented.

Chronic Obstructive Pulmonary Disease (COPD) affects nearly 12 million
individuals in the United States. In this study, the Nationwide Inpatient Sample (NIS)
dataset from the Healthcare Cost Utilization Project (HCUP) database was used to study
the various patient- and hospital-related characteristics of patients hospitalized with
COPD, for the years 2002, 2003, 2004, and 2005. Important outcome variables such as
hospital length of stay, total hospital costs, and in-hospital mortality; and the factors
associated with these outcomes were studied in hospitalized cases with a primary or
secondary (listed second on the discharge records) diagnosis of COPD

For the year 2005, the number of hospitalized cases with COPD listed as the
secondary cause of diagnosis (national estimate 1,426,723) were found to be more than
twice the number of hospitalized cases with COPD listed as the primary diagnoses
(national estimate 616,818). In another study, McGhan et al. (2007) found that patients
were more than four times likely to have a prior “non-COPD” hospitalization than a prior
COPD hospitalization; which highlights the high prevalence of co-morbid conditions in
patients with COPD.30 It has been reported that even in patients with severe COPD, a
large proportion of patients are admitted to the hospital for other comorbidities. Thus,
COPD is seldom labeled as a secondary diagnosis, and non-respiratory diseases account
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for > 50% of the underlying causes of death in COPD.17, 41, 42 Consistent with other
studies, the most prevalent co morbid conditions in patients with COPD were
pneumonia, hypertension, congestive heart failure, cardiac arrhythmia, and peripheral
vascular disease.17, 41 In our study, the number of in-hospital deaths was more than three
times in cases with COPD listed as the secondary diagnosis, as compared to the number
of deaths in cases with COPD listed as the primary diagnosis. Thus, it is likely that the
burden of disease associated with COPD is substantially underestimated. Some of the
other factors accounting for such an underestimation include reduction in the incidence of
COPD exacerbations requiring hospitalization (which would otherwise be labeled as
primary discharge diagnosis), due to outpatient treatment.43

Our findings from the 2005 NIS data showed that patients with COPD in the age
group 65-80 years had the highest number of hospitalizations (47.1%), with the mean age
being 68.83 years. This finding is similar to the results of a study by McGhan and
colleagues (2007), where the mean age of patients with COPD was found to be 68.81
years.30 Also, the proportion of in-hospital deaths was highest in the age group 65 and
above. These findings are in support of the natural history of COPD among smokers,
which describes that smoking behaviors start during youth, lung function decline
becomes apparent when smokers reach age 40-50 years, hospitalizations begin when
smokers reach age 50-69, and deaths occur when they reach age 60-79.44 It was seen that
patients with COPD, 65 years and older accounted for 66.1% of the hospitalizations.
This is in accordance with the fact that patients under Medicare accounted for 71.9% of
hospitalizations.
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The results showed that the number of hospitalized cases for COPD were higher
in females, as compared to males. This is consistent with results from the study using the
2003 National Health Interview Survey (NHIS), which indicated higher rates of
combined chronic bronchitis and emphysema in females than males.12 Han MK and
colleagues (2007) suggest that COPD prevalence in women is likely to increase now, as
women are living longer, there is increased tobacco use in women and they are exposed
to the same workplace risks as men.12 Also, some studies hypothesize that females may
be at greater risk of smoking induced lung function impairment for the same level of
tobacco exposure.12 Studies have demonstrated that in terms of impact on secondary care
COPD is a disease of the elderly and is becoming more common in women.31

COPD is considered to be disease of the “Caucasians”, and studies show that the
prevalence of COPD remains higher in Caucasians than in African Americans.45 Our
study results too showed the same pattern with Caucasians being most commonly
affected (85.5%) followed by African americans (7.4%) and Hispanics (4.7%).
Patients with the lowest median household income had more than twice the
number of hospitalizations as compared with those with highest income (33.9% vs
15.6%). Buist et al. (2007) reported that COPD is causally associated with cigarette
smoking and with adverse working conditions, both of which, in turn manifest a strong
socio-economic status (SES) gradients.46 Blanc et al. (2008) also observed that lower
SES was strongly linked to decreased odds of using tiotropium, a COPD medication
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introduced in recent years; and suggested that health care access and such SES gradients
in medication use represent a potential source of health disparities.47

Our study results showed that almost 46% of all the hospitalizations due to COPD
were reported in hospitals in the Southern region. This is in accordance with the report on
COPD mortality rates (1990-1997), funded by the Appalachian region commission;
which showed that distinct geographic patterns are evident in the distribution of COPD
death rates.48 The authors reported that high death rates from COPD are predominant in
the regions of Kentucky, West Virginia, Georgia, and Alabama; and all these states were
categorized as Southern region in the NIS dataset used in our study.

Our study results also showed that patients with COPD were more likely to be
admitted to large and urban setting hospitals. Increased hospitalizations of patients in
large urban areas may be explained in part by the larger proportion of hospitals in the
urban areas (urban hospitals: 2,926, rural hospitals: 2,001).49 Other possible explanations
may include larger hospitals having more respiratory consultants, more non-physician
specialist support, and greater availability of wider range of services.34

The mean hospital LOS per patient with COPD was found to be 4.69 days in
2005. Using hospital data from Spain, Iglesia et al. (2002) also reported the mean LOS to
be 4.6 days in 2001.50 However, the mean LOS reported by this study is significantly
lower than that reported by some other studies. Saynajakangas et al. (2004) reported the
mean LOS to be 6.8 days in 2001, while Kong and Bellmen (1997) found the mean LOS
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to be 6.5 days.29, 51 A possible explanation for the significant decrease in mean LOS in
the past few years may be due to the increasing costs of hospitalizations.52 Because of the
increasing charges, there is a possibility that many health plans may have begun to use
clinical practice guidelines regarding LOS to limit use of inpatient services.52 Kong and
Bellmen (1997) also found that the necessary LOS for patients with COPD may be
significantly less than actual LOS. After reviewing the practice guidelines and
conducting a retrospective study, the authors demonstrated that when patients are
classified as low risk according to the practice guideline, the hospital LOS could
potentially be shortened to 3.2 days, with probably little effect on quality of care.51

In our study, the LOS was observed to be higher in older people (age > 64 years)
and in females as compared to males. These results are in accordance with the findings of
the study by Saynajakangas et al. (2004), where it was seen that the LOS was longer for
older people and females, and the elderly females had the longest inpatient stays.29

Mawajdeh et al. (1997) conducted a retrospective review of medical records of
public and private hospitals and after controlling for all types of illness category, found
that insured patients exhibited statistically longer hospital LOS compared to uninsured
patients, possibly to avoid high hospital charges.53 Our study findings are consistent with
these findings, and the LOS was observed to be shortest for uninsured patients compared
to those with insurance coverage.

130

The LOS was found to be longer in hospitals in urban areas as compared to rural
areas, and was longest in hospitals with large bed-sizes. In our study, the LOS was found
to be longest in the Northeast region and, it was shortest in the Western region. The posthoc analysis showed a significant difference of 1.065 days in LOS between the Northeast
and the Western region. This is consistent with the results of a case study by Chassin
(1983), where a similar geographic variation was reported, LOS being longest in the
Northeast and shortest in the West.54

Similar to hospital LOS, total hospital costs were found to be higher in older
people (age > 64 years), and in females as compared to males. The possible reason for
higher costs could be the longer LOS. Patients with no insurance were found to have the
least hospital costs, and this is also in accordance with results of the study by Mawajdeh,
et al. (1997); where patients with no health insurance had substantially lower hospital
charges than those patients with insurance.53

The total hospital costs were higher for both Hispanics and African Americans, in
comparison to Caucasians. Most Hispanics and African Americans in our study sample
were found to be covered by Medicare and Medicaid. On conducting further analysis, it
was found that, of the sample population that lacked health insurance; Hispanics
accounted for 6%, African Americans accounted for 12%, while Caucasians accounted
for 78%. Further analysis also showed that African Americans had a higher average
number of procedures listed on the discharge records, as compared to Caucasians; which
could be suggestive of more disease severity among African Americans. Also cross
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tabulations showed that 52% of African Americans and 48% of Hispanics belonged to
lowest category of the median household income groups. Studies show that African
Americans have lower lung function than Caucasian.39 And Dransfield (2006) suggested
that racial differences in SES may explain this difference; as poverty, a known predictor
of lower lung function, is more common among African Americans.39

Another factor, which could explain the difference in disease severity could be
hazardous occupational exposure. The estimated fraction of COPD cases caused by
occupational exposure ranges from 15% to 31% among never-smokers.55 Minority
groups have historically been overexposed to hazardous industries, and a study based on
analysis of the National Health and Nutrition Examination Survey (NHANES) data
showed that the fraction of airflow obstruction attributable to workplace exposure was
lowest among Caucasians (21.5%), intermediate among African Americans (25.4%), and
highest among Hispanics (55.7%).55 Studies have been published that address racial
disparities in the application of smoking cessation programs, and influenza vaccination;
both of which are interventions known to alter COPD severity. One study reported that
smoking cessation counseling was offered less often to African Americans than
Caucasians (30% versus 42%), and another study showed that African American COPD
patients were less likely than their Caucasian counterparts to receive influenza
vaccination.39

The total hospital costs in urban areas were almost twice than those for rural
areas, and our results are in accordance with other studies which report that urban
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location of hospitals are associated with higher hospital charges and costs.56 On
conducting cross-tabulations, it was seen that most of the medium and the large bed-size
hospitals were located in the urban locations. This explains the total hospital costs being
higher for hospitals with medium or large-bed sizes.
The proportion of in-hospital deaths was substantially higher for those who were
65 years and older. The proportion of in-hospital deaths were also seen to be higher in
Caucasians, as compared to other races. Chatila et al. (2004) examined the smoking
habits in a group of patients with COPD and reported that for COPD- related surgeries,
African Americans presented at an earlier age and with fewer pack-years of smoking.45
Even in our study populations, most of the COPD patients aged 65 and above were
Caucasian. This can explain the higher in-hospital mortality among Caucasians. However
higher proportion of Caucasians in our study population could be a reason for these
findings.

Although males had a shorter hospital LOS, and lesser total hospital costs than
females; the proportion of males having an in-hospital death was higher as compared to
the proportion of females. Further analysis showed that males had a relatively higher
average number of procedures listed on their discharge records, as compared to females;
indicative of disease being more severe among males. Another possible explanation
could be that men seek medical care, only in the later stages of the disease; usually when
the disease is more severe, and the level of pain or discomfort is extremely high.
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Most of the COPD related deaths were observed in those aged 65 and above, and
this can also explain Medicare beneficiaries having substantially higher proportion of inhospital deaths.

CONCLUSIONS OF THE STUDY
In this study, patient- and hospital-related characteristics of COPD-related
hospitalizations were assessed. The study clearly demonstrated that disparities do exist in
COPD occurrence, and the outcomes related to the disease. The study showed that the
burden of disease associated with COPD is substantially underestimated, and that it
usually affects females, Caucasians, people aged 65 and above, and people from lower
income level groups. It was also seen that COPD most commonly affected people
located in the metropolitan areas, and also those from the southern region of the US.
Predictors for hospital LOS, total hospital costs, and in-hospital mortality for
hospitalizations due to COPD were also studied. Number of procedures and number of
diagnoses listed on the record; were seen to be important predictors for hospital LOS,
total hospital charges as well as in-hospital mortality. Hospital region, gender, and payer
were among other important predictors for hospital LOS; whereas for total hospital costs,
important predictors included hospital region, race, and patient location. Age and gender
were seen to be important predictors of in-hospital mortality.
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IMPLICATIONS OF THE STUDY
The findings of this study are important: they show that hospital resource
utilization is high in patients with COPD, and that there are disparities in hospital
resource utilization. The identification of the predictors of hospital LOS, total hospital
costs, and in-hospital mortality can be used to help the healthcare professionals in
identifying at-risk population who would benefit most from effective management of the
disease. The results can also be used by policy makers to make optimal resource
allocation decisions, such that there is equal access to care to the population at risk.
Appropriate disease management, and application of preventative care such as early
disease management and smoking cessation in identified population, can help in delaying
the progression of disease, preventing exacerbations, reducing mortality; and thus help in
lowering hospital admission rates and alleviating the economic burden of COPD.

LIMITATIONS OF THE STUDY
The present study has some limitations: the inherent limitations of a retrospective
database are applicable to this study as well. Some of these limitations include
dependency on previously recorded data in the chart, whose quality may be limited by
systematic or recorder bias, data coding-recoding errors, incomplete data, data quality,
and confounding factors. However, selection bias, inherent to large databases; can be
considered negligible here due to the complex sampling frame used in designing the NIS
database.
Because the NIS contains hospitals discharge records from only 20% of all
hospitals in the US, our projection of the number of COPD-related hospitalizations could
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have been underestimated. The NIS database did not provide any information about
disease severity, medication use or information on other potential confounding factors
which could affect the COPD-related outcomes such as smoking behavior, environmental
and occupational exposure. And the failure of considering these important confounding
factors, in our study; is a limitation.
NIS provides only discharge-level data, and not patient-level data. Therefore
hospital re-admissions rates could not be determined. Because of lack of patient
identifiers, patients who may have been hospitalized several times for the same condition;
could have been counted as separate individual records for analysis. As a result, the total
cost of hospitalization for each individual patient with COPD could not be determined.
And cost estimates for each hospitalization, as a separate event only; could be determined
in the study. The nature of the data also led to inability to determine any prevalence or
incidence rates related to COPD or the other associated co morbidities.
In NIS, the financial charge information provided is based on hospital charges and
not on actual costs or the amounts reimbursed by the payer. Also, several charges such as
emergency transportation costs and physician professional fees are not included as a part
of the hospital charges. Thus, our estimation may not completely or accurately reflect the
actual economic burden of COPD-related hospitalizations.
Only 29% of the discharge records had a race/ethnicity category listed on them,
and this could affect our results related to the racial-disparities.
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OPPURTUNITIES FOR FUTURE RESEARCH
Based on our study results, it is evident that disparities do exist among patients
with COPD. Further research needs to be conducted to better understand these
differences, and the related factors.
Because co-morbidities are an important aspect of COPD, further studies should
be conducted to determine the prevalence of the important co-morbid conditions in
patients with COPD. Also the differences in health outcomes and resource utilization
should be studied across the different cohorts of patients (patient with COPD and
different co-morbid conditions). Results from such a study, would help develop
treatment guidelines which would focus on early disease prevention and management of
co-morbid conditions in patients with COPD. Thus, providing an opportunity to avert
additional healthcare expenditure afflicted due to the co-morbid conditions in patients
with COPD. COPD is now being as a systemic disorder leading to development of comorbid conditions. Time-to-event or survival analysis studies could also provide an
insight about the hazard risk ratio of developing the co-morbid conditions after being
diagnosed with COPD.
Patient-level data, in the form of patient registry data or health care claims data
with patient identifiers can be used to determine the rate of rehospitalizations and the
identify the population at risk of rehospitalization among patients with COPD.
Health outcomes may vary across the different therapeutic drug classes which are
in prescribed in patients with COPD. Recent studies have shown that the beta-agonists
prescribed in patients with COPD have been associated with an increased risk for
cardiovascular diseases. Health care claims data with prescription drug information,
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could be used to study the healthcare expenditure on prescription medications, and the
differences which may exist in treatment outcomes; across the different treatment groups.
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